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ABSTRACT 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF TAMANDARIN B ANALOGS 
 
Kenneth M. Lassen 
 
Madeleine M. Joullié 
 
The tamandarin and didemnins are a class of cyclodepsipeptides that have shown 
a wide range of biological activity.  The didemnins have demonstrated antitumor, 
antiviral and immunosuppressive activity at low nano- and femtomolar levels.  Didemnin 
B was the first marine natural product to enter clinical trials in humans in the United 
States.  The structures of tamandarins A and B were reported in 2000 and possess almost 
identical structure and biological activity to didemnin B.  These compounds have shown 
impressive biological activity and some progress has been made in establishing structure-
activity relationships. However, their molecular mechanism of action is still unclear. The 
goal of the present research was to further the understanding of the processes underlying 
the biological activity through the preparation of designed analogs. 
  
Chapter 1 deals with the synthetic background of the tamandarins and the 
optimization of tamandarin B macrocyle for the preparation of specific analogs. 
 
 Chapter 2 describes the development of three tamandarin B/didemnin hybrid 
analogs.  Their synthesis utilized a high-yielding method to form the tamandarin B 
macrocycle and a concise approach to the three desired side chains that employed 
common intermediates. 
 
 Chapter 3 focuses on the synthesis of Lys3 tamandarin M.  This Lys3 modified 
macrocycle was designed for attachment to a biological probe in order to clarify the 
mechanism of action.  Lys3 tamandarin M was designed so that the attachment to the  
biological probe would allow for an intact side chain which is known to be the site of the 
activity. 
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Chapter 1 
1.1) Isolation and Structural Assignment  
In 1981 Rinehart reported the structures of didemnins A (1), B (2), and C (3).1 These 
natural products were isolated from tunicates from the family Trididemnum solidum at 
various sites in the Carribean.  Methanol-toluene extracts in shipboard assays showed 
excellent antiviral (RNA and DNA viruses) activity.2 The extracts also showed potency 
against L1210 murine leukemia.  These compounds were separated in the following 
manner: The methanol-toluene extracts were washed with aqueous NaNO3.  The aqueous 
layer was back-extracted with chloroform and concentrated.  Initial purification by silica 
gel chromatography, followed by preparative thin layer chromatography yielded pure 
didemnin A (1) (major component, 236 mg), didemnin B (2) (minor component, 42 mg), 
and didemnin C (3) (trace component, 20.2 mg).   The structures of these natural products 
were determined by hydrolysis (acid and basic) of the parent compounds, and NMR and 
MS analysis of the resulting fragments.  The original proposed structures of these 
bioactive natural products are shown in Figure 1.1. 
NH
O
O
OH
HN O
H
N
OO
N
OMe
O
N
O
O
NR
Pro4
N,O-Me2Tyr
5
Thr6
N-Me Leu7
Leu3
O
O
Sta1
Hip2
R= Me, R1=                                        Didemnin B (2)
O
OH
N
R= Me,  R1= H    Didemnin A (1)
O
O
OH
R= Me, R1=                                       Didemnin C (3)
Pro8
Lac9
 
Figure 1.1: Originally proposed structures of didemnins A (1), B (2), and C (3) and 
didemnin numbering nomenclature. 
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It was determined that the didemnins consisted of a 23-membered macrocyclic 
depsipeptide and a peptide side chain.  The macrocycle was divided into seven units but 
consisted of three main structural features.  The first was the statine (Sta1) fragment. This 
unit consisted of a δ-amino-β-hydroxyester.  The second major fragment was the 
hydroxyisovalerylpropionyl (Hip2) unit, which consisted of a β-keto-α-methyl-amide.  
The last portion was a tetrapeptide fragment, which consisted of a leucine (Leu3), proline 
(Pro4), N,O-Me2-tyrosine (N,O-Me2-Tyr5), and threonine (Thr6) residues.  The overall 
differences in this class of molecules lie in the side chains.  Didemnin A (1) had the 
shortest chain which consisted of an N-Me-D-Leucine (N-Me-Leu7) residue.  In didemnin 
B (2), the side chain was extended by two amino acid units; a proline (Pro8) and lactyl 
(Lac9) unit.  Finally, didemnin C (3) had an additional lactyl residue in the side chain, 
attached to didemnin A.   
The original structure of the didemnin macrocycle (2, Figure 1.2) turned out to be 
incorrect in two portions of the molecules.  Guyout and co-workers reported the isolation 
and characterization of a depsipeptide from Trididemnum cyanophorum, which they 
named isodidemine-1.3 Extensive NMR studies in deuterated benzene revealed an 
isomeric statine residue, which consisted of two distinct methyl groups.  The name 
isostatine was given to this amino acid.  When dissolved in deuterated chloroform the 
methyl peaks of the isostatine unit of didemnin B were unresolved.  Changing NMR 
solvents led to the correct assignment of this residue in which the statine residue was 
replaced by an isostatine moiety.  This result was confirmed by Banaigs, who established 
the correct structure by comparison of chemical degradation products with synthetic 
intermediates.4 The Hip residue was originally assigned the incorrect steoreochemistry.  
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In a study reported by Joullié and Ewing, they found that the stereochemistry of this 
residue was (2S, 4S) diastereomer, not the originally reported (2R, 4R) diastereomer. This  
revision led to the correct structural assignment of didemnin B (4) (Figure 1.2).5   
NH
O
O
OH
HN O
H
N
OO
N
OMe
O
N
O
O
N
O
O
Sta1
NH
O
O
OH
HN O
H
N
OO
N
OMe
O
N
O
O
N
O
O
O
N
O
OH
O
N
O
OH
Correct structure of Didemnin B (4)Proposed structure of Didemnin B (2)
Ist1
 
Figure 1.2:  Comparison of proposed and correct structure of didemnin B. 
 
1.2) Antiviral Activity 
 Onboard assays of the initial extracts revealed that the components of the mixture 
were active against herpes simplex virus (HSV-1) cultured from CV-1 (monkey kidney 
cells).  Later studies confirmed that the extracts were active against DNA (HSV-1, HSV-
2, vaccinia) and RNA (influenza A, parainfluenza 3, equine rhino, and coxsackie A21) 
viruses.  Upon separation of the extracts it was found that didemnin B was a more potent 
antiviral agent than didemnins A or C in the lines tested (table 1).2 
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Table 1: Antiviral and toxicity data ID50 (µg/mL) 
 Didemnin A Didemnin B Didemnin C 
Toxicity-ML cells 12 <1.5 6 
Antiviral-COE virus <1.5 <1.5 <1.5 
Toxicity-Vero cells 25 25 50 
Antiviral-ER virus <1.5 <1.5 <1.5 
Antiviral-HSV-1 <1.5 <1.5 <1.5 
Antiviral-HSV-2 <1.5 <1.5 <1.5 
  
 In this study the Vero cells were used for herpes simplex virus (HSV) I and II.  
ML cells were used for equine rhino and coxsackie (COE).  As shown in the Table, even 
though didemnin B exhibited the most potent in vitro antiviral activity it was also 
significantly more cytotoxic than didemnins A and C.  This trend was especially true in 
the RNA viruses.  Maldonado and co-workers  reported that didemnin A was effective at 
blocking the replication of three types of Dengue viruses in vitro.6  During these studies 
they reported that didemnin A inhibited the formation of virus plaques by 50% at 
concentrations of 0.18 to 0.25 µg/mL.  At these concentrations no cytotoxic effects were 
observed.  Unfortunately, concentrations above 5 µg/mL yielded a high level of 
cytotoxicity.  A group from Upjohn disclosed the results from an antiviral trial in mice 
using didemnins A and B.7 They found that these were both effective reagents at reducing 
the severity of cutaneous herpes simplex virus.  The downside to this treatment was that 
these reagents were effective but needed to be used two days prior to the infection and 
continued for 5 days afterward.  Unfortunately, treatment of the mice with didemnin A or 
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B after the infection was contracted resulted in no antiviral activity.  Canonico showed 
that mice infected with Rift Valley fever (RVF) that were treated with 0.25 mg/kg/day 
had a 90% survival rate.8 To go along with this result they also reported that there was 
some unspecified drug related deaths.  In order to prevent this from occuring, the dosage 
was lowered to 0.20 mg/kg/day, but the survival rate decrease to 40% using this protocol.  
With these results in hand, the use of the didemnins as clinical antiviral agents seemed 
unlikely. 
 
1.3) Antitumor Activity 
 In the isolation report Rinehart noted that didemnins A and B showed potential as 
antitumor agents.1 Didemnin A and B showed 50% growth inhibition in L1210 cells at 10 
and 1 nM respectively.  Didemnin B was generally more potent than didemnin A in vitro 
and in vivo.  This difference was confirmed later by Rinehart in a study where mice with 
P388 leukemia tumors were treated with doses of these compounds.9 Didemnin B 
extended survival time to 40% when treated with 0.06 mg/kg, whereas didemnin A 
needed doses of 8 mg/kg to give the same survival time.  This same trend was also seen 
in the case of B16 melanoma.  In 1983 Jiang reported the activity of didemnin B against 
human tumor cells obtained via biopsy.10 Tests demonstrated that cells from lung, breast, 
and kidney cancers (11 cell lines total) were sensitive to treatment with didemnin B.  
Each of the cell lines were treated in two different manners.  They were treated with 
didemnin B for 1 hour and by continuous exposure.  When exposed continuously the 
mean ID50 value was 0.0042 µg/mL and when exposed for 1 hour was 0.046 µg/mL.  
Continuous exposure led to potency 10 times that of just 1 hour exposure.   
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 These results plus other encouraging preclinical tests led to phase I and II clinical 
trials.  Didemnin B became the first marine natural product to be used in clinical trials in 
the United States for its anticancer activity.11 Trials were conducted on a variety of 
different types of cancers including non-small-lung, metastatic breast, epithelial ovarian 
carcinoma, and non-Hodgkin’s lymphoma, among others. These trials were eventually 
terminated due to toxicity and poor results.  Lowering dosages did not give the desired 
results.  When higher dosing levels were employed, significant toxicity occurred.  The 
side effects included nausea, vomiting, neuromuscular toxicity, and elevated levels of 
hepatic enzymes, among others.  These trials were eventually terminated due to the poor 
efficacy and high levels of toxicity.  Nevertheless it was suggested that lower doses 
required for antitumor activity in a continuous exposure regimen might lead to an 
enhanced therapeutic index.12 Another didemnin analog, dehydrodidemin B, which will 
be discussed later, is currently in clinical development, due to its higher potency and 
lower toxicity.   
1.4) Total Syntheses 
 With their potential as therapeutic reagents and novel structures, the didemnins 
became attractive synthetic targets.  To date several total syntheses have been completed 
of didemnins A, B, or C and closely related analogs.  The Rinehart group was the first 
group to complete the total synthesis of didemnins A, B, and C.13 The key step in their 
synthesis was the cyclization at the Ist1-Thr6 junction (5) to form the desired macrocyclic 
ring (6), using EDCI as the coupling reagent in 18% yield (Scheme 1.1).  There were 
drawbacks to this synthesis. It had a low yielding cyclization and was not conducted in a 
stereocontrolled manner.  The methyl group of the Hip2 residue was carried through the 
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synthesis as a mixture of epimers.  This epimeric mixture was eventually resolved by 
HPLC, but not until the final steps of the synthesis. Lastly the N-Me-D-Leu7 of the side 
chain was installed early and could be undesired in some side-chain analogs.  Although 
this synthetic route lacked overall efficiency, it was the first one reported and it provided 
a route to the natural product at a time when this material was scarce and the medicinal 
chemistry community was extremely interested in this class of compounds. 
NH
O
HO O
H
N
OO
N
OMe
O
N
O
O
O
O
NCbz
O OH
NH3TFA
EDCI, NMM, HOBt, 18%
NH
O
O
OH
HN O
H
N
OO
N
OMe
O
N
O
O
NCbz
O
O
 5                                                                                                                           6  
Scheme 1.1:  Rinehart’s method of macrocyclization.   
The second reported total synthesis completed was by the Schmidt group.14-17   This 
synthesis featured three key contributions.  The first was the preparation of the more 
expensive (2R, 3S)-alloisoleucine from the less expensive (3S, 2S)-alloisoleucine 
diastereomer (Scheme 1.2) to be used in the synthesis of the Ist1 residue.  This synthetic 
route was done in a five-step process starting from the less expensive diastereomer (7).  
First, treatment of (3S, 2S)-alloisoleucine with isoamyl nitrate led to 9, followed by 
esterification led to α-hydroxy methyl ester 9.  Next mesylation gave 10, displacement 
with NaN3 and subsequent hydrogenation led to the desired amino acid salt (11) protected 
as its methyl ester. 
 8 
O
OH
NH2
7                                                                                  8                                                                                       9
1) i-C5H9ONO, AcOH, 55%  HCl/MeOH, 86%
O
OH
OAc
 MsCl, pyridine, CH2Cl2, 86%
O
OMe
OMs
O
OMe
OH
1) NaN3, DMF
2) H2, Pd/C, HCl/EtOH, 76% O
OMe
NH2•HCl
10                                                                                             11  
Scheme 1.2:  Schmidt’s synthesis of (2R, 3S)-alloisoleucine methyl ester. 
 
The second key contribution by Schmidt was a novel cyclization strategy (Scheme 1.3).  
Starting from linear precursor 12, the trichloroethyl ester protecting group was removed 
under standard conditions and was directly converted to a pentafluorophenyl ester.  Next 
the Boc group was removed using TFA to form the activated free linear precursor as its 
TFA salt 13.  The salt was dissolved in chloroform, and 1M NaHCO3 was added to the 
solution, and shaken rigorously for 5 minutes.  Using this procedure the authors were able 
to isolate the desired macrocycle (14) as a mixture of separable epimers in 75% yield 
over the four steps described.  
N
Boc
O
N
OMe
O
O
NHCbz
O
NH
OH
O
O
O
N
H
O
O O
CCl3
1) Zn, AcOH/H2O
2) C6F5OH, DCC, CH2Cl2
3) TFA/CH2Cl2
4) 1 N NaHCO3, CHCl3, 75%
NH
O
O
OH
HN O
NH
CbzOO
N
OMe
O
N
O
O
O
12                                                                                                                       14  
Scheme 1.3:  Schmidt’s method of cyclization.   
Schmidt’s third key contribution to the didemnin literature was the conversion of 
undesired (2R)-epimer (15) to the desired (2S)-epimer (16) of the HIP unit.  This could be 
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done under basic or acidic conditions as shown below (Scheme 1.4).  The Schmidt 
synthesis was significantly better than Rinehart’s synthesis.  Specifically Schmidt’s 
cyclization yield was three times higher than that of Rinehart.  Also the conversion of the 
undesired to the desired epimer greatly increased the overall efficiency of the synthesis. 
NH
O
O
OH
HN O
NHCbz
OO
N
OMe
O
N
O
O
O
15                                                                                                                        16
TFA or DBU in CH2Cl2, 100% NH
O
O
OH
HN O
NHCbz
OO
N
OMe
O
N
O
O
O
 
Scheme 1.4: Conversion of undesired (2R)-epimer to desired (2S)-epimer of the HIP unit. 
The third completed total synthesis was by the Jouin group.18 Their synthesis was 
somewhat different due to the fact that they synthesized nordidemnin B.  Nordidemnin B 
differs from didemnin B in the fact that nordidemnin B possessed a norstatine (Nst) 
residue instead of the isostatine (Ist) residue present in didemnin B.  The synthesis 
featured two key points.  The first was the use of thioester activation using a transition 
metal to facilitate amide bond formation (Scheme 1.5).   This step was accomplished by 
adding two equivalents of CuI and one equivalent of triethylamine to amine 17 and 
thioester 18.  This reaction was completed in 30 minutes and gave 19 in 85% yield.   
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Scheme 1.5:  Jouin’s method of linear precursor formation via thioester activation and 
cyclization. 
The cyclization proceeded in good yield.  The cyclization occurred at the same position 
of the macrocycle that Rinehart13 used, at the Ist1-Thr6 junction (Scheme 1.5).  Instead of 
using EDCI, Jouin used BOP in the presence of NaHCO3 to afford a 54% yield of 20.  
While this yield was not as high as that reported Schmidt, it was still a marked 
improvement over that of Rinehart’s.   
The Shioiri group was the next laboratory to publish their synthesis.19 Their synthesis 
featured one of the highest yielding cyclizations to date.  The authors closed the 
macrocycle at the Pro4-N,O-Me2-Tyr junction to facilitate this high yielding ring closure. 
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Linear precursor 21 was subjected to hydrogenolysis conditions to remove the terminal 
protecting groups.  Cyclization was achieved using BOPCl and triethylamine at a 1mM 
concentration to afford the desired macrocycle (22) in a 68% yield (Scheme 1.6).  A 
disadvantage of this synthesis was that the HIP residue was carried through as a mixture 
of epimers and the undesired one was separated at a point prior to cyclization.   
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Scheme 1.6:  Shioiri’s cyclization protocol to yield protected didemnin A. 
 
Another group to synthesize the didemnins was that of Joullié.20 This synthesis had two 
key features.  The first and most important was that they synthesized the HIP2 residue in 
a stereocontrolled fashion.  This synthesis started with the addition of (E)-silylketene 
thioacetal 23 to protected hydroxy aldehyde 24 in a chelation-controlled aldol reaction to 
form the desired product (Scheme 1.7).  Subsequent reduction of the thioester with 
LiAlH4 gave diol 25.  Silyl protection of the primary alcohol and MOM protection of the 
secondary alcohol led to 26.  Removal of the benzyl group with sodium and liquid 
ammonia followed by acetate formation resulted in compound 27.   
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Scheme 1.7:  Stereocontrolled formation of the HIP residue.   
The second key feature to this synthesis was the cyclization (Scheme 1.8).  Macrocycle 
formation occured at the Leu-HIP junction to form the desired amide bond. Linear 
precursor 28 was exposed to AcOH to remove the TBS group.  A two-step oxidation 
procedure was used to convert the primary alcohol to the carboxylic acid.  First the 
alcohol was oxidized to the aldehyde using a Swern conditions.21 This unstable aldehyde 
was directly oxidized with KMnO4 to yield the desired acid.  Hydrogenolysis, followed 
by lactamization provided the macrocycle using diphenyl phosphoryl azide.  While this 
cyclization only afforded a 40% yield, using this condition allowed for the reaction to 
proceed in a more concentrated solution (10 mM).  This is a dramatic improvement over 
the other syntheses mentioned because the order of magnitude difference in concentration 
(1 mM vs. 10 mM) allows scale-up of the synthesis.  With the desired macrocycle in 
hand, the MOM group was removed using Me2BBr to yield a secondary alcohol, which 
was oxidized to give the fully functionalized macrocycle 30.  The stereocontrolled 
synthesis of the HIP residue is the cornerstone of this route.  While installation of the 
Hip2 residue lengthens the route to the macrocycle, late stage epimerization is 
unnecessary.  
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Scheme 1.8:  Macrolactamization strategy used by Joullié. 
 
The last didemnin macrocycle synthesis to date is that of Lloyd-Williams and Giralt.22 
Their synthesis is very similar to that of Shioiri.19 Cyclization took place at the Pro4-N,O-
Me2Tyr junction.  However, there were a few key differences.  The first was the coupling 
reagent they chose, HATU instead of BOPCl to provide 32 from 31 (Scheme 1.9).  The 
second was that the linear precursors were slightly different.  The first difference was that 
the N-Me-D-Leu7 residue was not present in the Lloyd-Williams/Giralt route as it was in 
the Shioiri route.  The second difference was that the secondary hydroxyl group was 
unprotected, whereas in the Shioiri route, it was protected as a TBS ether.  The 
cyclization proceeded in a 76% yield (Scheme 1.9). 
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Scheme 1.9:  Macrocyclization procedure used by Lloyd-Williams and Giralt. 
1.5) Other Relevant Didemnins 
 
Dehydrodidemnin B (33, Figure 1.3) was isolated by Rinehart and coworkers in 1991 
from Mediterranian colonial tunicate Alplidium albicans.23 Initial studies indicated that 
this new member of the didemnin family was three to five times more active than 
didemnin B in vivo and was effective at treating some forms of leukemia, melanoma, and 
lung cancers.  The only difference between the two compounds is dehydrodidemin B (33) 
possesses a ketone in the side chain instead of a secondary alcohol (Figure 1.3) 
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Figure 1.3:  Structure of dehydrodidemnin B and how it differs from didemnin B. 
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  Since only small amounts of this more biologically potent analog were isolated, initial 
efforts to make material more available for testing, semisynthetic methods were used to 
make this natural product from didemnin A.  The first total synthesis of dehydrodidemnin 
B was reported by Lloyd-Williams and Giralt in 1997, along with their synthesis of 
didemnin A.22 Their strategy involved synthesizing didemnin A and then coupling the 
remaining residues of the side chain on to form this new natural product (Scheme 1.10).   
Didemnin A was made in a similar manner as described in Scheme 1.9.  Pyruvic acid (34) 
was coupled to Pro-OBn•HCl (35) using DCC to form the desired product 36.  
Hydrogenolysis conditions removed the benzyl ester to afford free acid 37 (Scheme 
1.10).   
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Scheme 1.10:  Formation of the Pyr-Pro-OH portion of dehydrodidemnin B. 
This free acid (37) was then coupled to didemnin A using PyBroP to yield 
dehydrodidemnin B (33) in 62% yield (Scheme 1.11).   
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Scheme 1.11:  Completion of dehydrodidemnin B. 
Interestingly the natural and synthetic material eluted as two distinct fractions via HPLC.  
Isolation of each peak and reinjection resulted again in two peaks in a 55:45 ratio.  
However coalescence of the peaks is observed when the column is heated to 50 ºC.  
These observations along with NMR studies show that there is a slow isomerization of 
rotational isomers.  The conformation of these isomers were resolved using NMR (Figure 
1.4). One had the amide carbonyl of the pyruvyl residue hydrogen bonded to the Thr6 
amide proton (38).  In the second conformation the pyruvyl ketone is hydrogen bonded to 
the same amide proton (39). 
didemnin macrocycleN
O
HNMe
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O
O
didemnin macrocycle
N
O
HNMe
O
N
O
O
38                                                                          39  
Figure 1.4:  Solution conformations of dehydrodidemnin B. 
The ketone present in this natural product has enhanced its therapeutic value 
significantly.  During the preclinical and phase I trials dehydrodidemnin B showed 
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enhanced antitumor activity over didemnin B.24 Of even greater importance, the toxicity 
was significantly decreased.  The observed neuromuscular and cardiotoxicity seen with 
didemnin B in phase II clinical trials were reduced significantly using dehydrodidemnin 
B.  To date this compound has completed phase II clinical trials and it is currently 
entering phase III clinical trials for multiple myeloma under the name Aplidin®. Aplidin® 
has been designated an orphan drug by the European Commission (EC) and FDA for 
acute lymphoblastic leukemia and multiple myeloma.25 Unfortunately reasons for this 
enhanced efficacy remain unclear.  The conformers shown above (Figure 1.4) are 
relatively similar to each other and to that of didemnin B, so the authors imply that this 
enhanced activity is not due to conformation.   
Didemnin M is another important member of this family of natural products.26 Its 
structure was originally reported by Banaigs and co-workers in 1994.27 This compound 
was first named didemnin H, but its name was changed to didemnin M.  Banaigs was able 
assign the structure based on 1H, 13C, and DEPT NMR experiments, along with mass 
spectral data.  The 13C NMR data clearly showed the presence of four additional carbonyl 
resonances compared to that of didemnin B.  The mass spectral fragmentation pattern 
revealed that this compound shared the didemnin B core but possessed two additional 
amino acid residues (Gln and pGlu).  The structure of didemnin M (40) is shown below 
in Figure 1.5.     
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Figure 1.5:  Structure of Didemnin M. 
 
In terms of biological activity this compound is a potent antitumor and 
immunosuppressive reagent in vitro.  In a two way mixed lymphocyte reaction (MLR), 
didemnin M showed an IC50 of 0.76 pM and is one of the most potent 
immunosuppressive reagents known.  While no total syntheses have been reported, two 
semi-synthetic methods have been published.  Joullié and co-workers have developed a 
route to an analog with a simplified didemnin macrocycle and the didemnin M side 
chain.28    Crews developed a solution and solid phase semi-synthetic route to didemnin 
M.29 The solution phase synthesis began with benzyl protection of D-methyl lactate (41), 
followed by hydrolysis of the methyl ester to yield carboxylic acid 42.  This acid was 
then coupled to L-Pro-OtBu•HCl and subsequent hydrogenolysis led to 43. Mitsonobu 
type esterification using DEAD with Fmoc-Gln(Trt)-OH yielded the desired ester 44.  
Fmoc removal followed by coupling to pGlu-OH yielded the fully elaborated target (45) 
in good yield.  Protecting group removal using TFA provided a carboxylic acid, which 
was coupled to didemnin A to yield didemnin M (Scheme 1.12). 
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Scheme 1.12:  Crews solution phase semi-synthesis of didemnin M.  
The solid phase synthesis was done in a similar manner as the solution phase using Wang 
resin and an Fmoc protecting group strategy (Scheme 1.13).  Starting from Fmoc-Pro 
functionalized Wang resin (46), the protecting group was removed and the free amine 
was coupled to O-Fmoc-Lactic acid using HBTU to form 47.  The Fmoc group was 
removed to give a free alcohol, which was esterified with Fmoc-Gln(Trt)-OH to give 48.  
Acetylation with Ac2O capped any unreacted alcohol. Again removal of the Fmoc group 
with piperidine and coupling to pGlu-OH gave fully elaborated compound 49.  Finally, 
removal of the remaining protecting groups, followed by release from the solid phase 
gave free acid 45, which was coupled to didemnin A to yield didemnin M.   
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Scheme 1.13:  Crews solid phase semi-synthetic approach to didemnin M. 
The Rinehart approach is different from that of Crews in two ways.   Rinehart used 
didemnin B as his natural product starting point and his synthesis started from the 
terminal residue and worked inward instead of working outward (Scheme 1.14).30  
Rinehart started from pGlu-OH and used a three step, one pot procedure to obtain the 
desired acid to react with didemnin B.  First activation of pGlu-OH (49) as a mixed 
anhydride and condensation with Gln-OtBu yielded the desired amide bond.  Acidic 
workup removed the ester group to give the desired acid (50).  Activation of the acid 
again as a mixed anhydride and addition of didemnin B yielded didemnin M (40) in 79% 
yield. 
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Scheme 1.14:  Rinehart semi-synthetic route to didemnin M. 
The Joullié group has made a number of potent synthetic didemnin side chain analogs. 
The most biologically active of these have been modified in the Pro8 residue (Figure 1.6). 
Of the analogs made, the amide bond surrogate (Ψ[CH2NH2]) analog in which the proline 
carbonyl is reduced to a methylene group is the most synthetically accessible.31,32 
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Figure 1.6:  Structure of didemnin B amide surrogate analog (51). 
 The synthesis of the analog started with N-methylation of N-Boc-D-Leu-OBn (52) with 
methyl iodide and NaHMDS to yield 53 (Scheme 1.15).  Removal of the Boc group 
followed by reductive amination with N-Boc-prolinal led to amine 54 in good yield.  
Removal of the Boc group followed by coupling to L-lactic acid afforded the fully 
functionalized side chain (55).  Hydrogenolysis followed by coupling to the didemnin 
macrocyclic salt led to the final product.  
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Scheme 1.15:  Synthesis of Ψ[CH2NH] surrogate (51). 
This amide surrogate proved to be more active in vitro than didemnin B.  In the NCI-60 
tumor cell screen compound 51 had a mean GI50 of 4 nM compared to didemnin B, which 
had a mean GI50 of 13 nM.  This compound also seemed to be slightly less toxic with and 
LC50 of 3.0 µM compared to that of didemnin B was has a mean LC50 of 3.8 µM.   
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1.6) Tamandarins A and B 
In 2000 Vervoort and Fenical reported the structures of tamandarins A and B.33 These 
compounds were isolated from an unidentified didemnid on a shallow-water reef off the 
coast of the Brazillian village of Tamandaré.  Initial biological testing showed that the 
crude extracts of this tunicate showed potent growth inhibitory activity in human colon 
tumor cell line HCT 116.  This crude mixture was separated via column chromatrography 
and reverse phase HPLC to yield Tamandarin A (56) and Tamandarin B (57) (Figure 
1.7). 
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Figure 1.7:  Structures of tamandarins A (56) and B (57) 
It was immediately obvious by NMR and MS analysis that tamandarin A (56) was almost 
structurally identical to didemnin B (4).  Analysis of the 1H NMR spectrum of 
tamandarin A showed a strong resemblance to the structure of didemnin B.  Present in 
both spectra were three NH protons in the amide proton region, along with a para-
substituted phenyl ring.  The major differences between the two compounds were further 
upfield in the spectra.  Tamandarin A posses 10 α-hydrogens, and didemnin B possesses 
11.  Both compounds possess three methyl groups present on heteroatoms, but didemnin 
B has 11 additional methyl groups where tamandarin A only has 10.  Importantly 
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Tamandarin A did not posses a ketone resonance in the 13C NMR spectrum where 
didemnin B did. Mass spectral analysis of tamandarin A showed the parent ion at 1056 
amu (M+H) and its fragmentation pattern revealed the loss of the Lac9 and Pro8 as one 
unit, 169 (m/z 887), and the loss of 127 (m/z 760) for the loss of the N-MeLeu7 residue.  
This observation proved that the side chain region of tamandarin A and didemnin B were 
identical and that the structural differences were in the macrocyclic ring.  Next ROESY 
and HMBC experiments provided the connectivity of tamandarin A.  This data also 
showed the differences between tamandarin A and didemnin B (Figure 1.8).  Where 
didemnin B possesses the more complex Hip2 residue as described above, tamandarin A 
possesses the simpler Hiv2 (hydroxyisovaleric acid) moiety. Tamandarin B resembles 
nordidemnin B, possessing a norstatine residue at position one instead of an isostatine 
unit. To unambiguously prove their absolute stereochemistry tamandarins A and B were 
subjected to basic hydrolysis and the resulting acids were capped as methyl esters and the 
resulting fragments were analyzed (Scheme 1.16).  The same exercise was also done with 
didemnin B and nordidemnin B for fragment comparisons.   
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Scheme 1.16:  Hydrolysis and methylation of tamandarins A and B. 
 24 
For tamandarin A, hydrolysis product 59 was identical via 1H NMR, optical rotation, and 
tandem mass spectral analysis to didemnin B fragment revealing that it had an isostatine 
residue present.  The same observation applied to tamandarin B in which fragment 60 
matched the hydrolysis product from nordidemnin B, revealing that it possessed a 
norstatine fragment at position one.  Acid catalyzed hydrolysis of peptide fragment 58 
and preparation of the isolated amino acids as their Marfey’s derivatives revealed the 
absolute configuration of the corresponding amino acids, which were identical to those in 
didemnin B.  Lastly the hydroxyisovaleric acid residues absolute configuration was 
determined by Mosher ester analysis.  The core the tamandarins A and B and didemnin B 
are shown below to illustrate the structural differences between the two classes of 
molecules (Figure 1.8). 
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Figure 1.8: Comparison of the didemnin and tamandarin cores. 
The solution phase conformation of tamandarin A appears to be similar to that of 
didemnin B.  The same hydrogen bonds are present and stabilize the configuration 
(Figure 1.9).  There are three hydrogen bonds; the lactyl carbonyl to the amine proton of 
threonine (Lac9 CO-Thr6 NH), methyl leucine carbonyl to the amine proton of leucine 
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(MeLeu7 CO-Leu3 NH), and the leucine carbonyl to the amine proton of isostatine (Leu3 
CO-Ist1 NH).  These hydrogen bonds produce a “bent figure-eight” macrocycle with the 
side chain coming off the Thr6 nitrogen sitting above it. 
 
Figure 1.9: Drawing representing the solution conformation of tamandarin A.33 
 
1.7) Total Syntheses of the Tamandarins 
Both tamandarins A and B were synthesized by Joullié and coworkers.34-36 Both 
syntheses were convergent and used the same cyclization strategy to form the parent 
macrocycles.  The retrosynthesis is shown in Scheme 1.17.  The parent natural products 
(56 and 57) are cleaved into the Boc protected macrocycle (61) and the side chain acid 
(62).  The macrocycle is then opened at the Thr6-Nst (or Ist)1 residues to form linear 
precursor 63.  Lastly, linear precursor 63 is cleaved at the Leu3-Hiv2 junction to form 
tetrapeptide 64 and allyl ester 65.  This cyclization strategy is different than that used by 
the Joullié group in their didemnin synthesis.  Instead of cyclization at the Hip2-Leu3 
junction as was used in the didemnins, they chose to cyclized at the Thr6-Nst/Ist1 junction 
to form the macrocycle.  
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Scheme 1.17:  Retrosynthesis of tamandarins A and B. 
 
The forward synthesis began with the formation of tetrapeptide fragment 64.  Cbz-L-Leu 
(66) was coupled to L-Pro-OMe  using DCC and HOBt to form the desired amide bond in 
excellent yield.  The methyl ester was hydrolyzed using LiOH to yield free acid 67 in 
high yield to give the left half of the tetrapeptide fragment.  To form the right half of the 
tetrapeptide moiety Cbz-L-Tyr (68) was dimethylated to yield N,O-Me2-Tyr.  This 
intermediate was then esterified with N-Boc-L-Thr-OSEM using isopropenyl 
chloroformate in 87% yield.  Hydrogenolysis conditions resulted in the removal of the 
Cbz group, to give the free secondary amine (69), which was then coupled to acid 67 
using BOP-Cl to give fully protected tetrapeptide fragment 64.  Again hydrogenolysis 
conditions resulted in removal of the Cbz group to give free amine 70 (Scheme 1.18). 
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Scheme 1.18: Synthesis of tetrapeptide fragment of the tamandarins. 
 
The Hiv-Norstatine (Isostatine) fragment was synthesized next (Scheme 1.19).  First, 
Cbz-D-Val (71) was esterified with pentafluorophenol using EDCI to yield activated ester 
73.  Next this activated ester was condensed with the lithium enolate of methyl acetate to 
yield a β-keto ester, which was subsequently reduced to alcohol 75.  Protection of this 
alcohol as its TIPS ether and methyl ester hydrolysis yielded carboxylic acid 77.  
Unfortunately, attempted esterification with SEM ester 79 afforded lactam 80 as the 
major product, which was the result of intramolecular lactamization of the activated 
carboxylate of 77.  A change of conditions from carbodiimide activation to a mixed 
anhydride did not change the result to favor 82. 
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Scheme 1.19:  Synthesis of Hic-norstatine (isostatine) residue. 
 
The solution to this problem was to change the protecting group on the hydroxyisovaleric 
acid residue from SEM to allyl (84, Scheme 1.20). With the allyl group, the esterification 
proceeded in 65% yield.  Removal of the allyl group with Pd(PPh3)4 and morpholine 
yielded the free acid 87.  
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Scheme 1.20:  Synthesis of carboxylic acids 87 and 88. 
 29 
Using PyBroP or HATU to couple amine 70 with acid 87 only resulted in 20-30% yields 
of product 89 (Scheme 1.21).  
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Scheme 1.21:  Synthesis of tamandarins A and B linear precursors, 
 
The optimization involved pre-activation of the carboxylic acids as their 
pentafluorophenyl esters to afford the amide bonds in 79% yield and gave the free linear 
precursors (Scheme 1.22). 
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Scheme 1.22:  Synthesis of tamandarins A and B linear precursors. 
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With a high yielding route to the linear precursor in hand, the protecting groups were 
removed and the compound was cyclized to yield the desired macrocycle.  The first steps 
taken towards the tamandarin macrocycles were removal of the two terminal protecting 
groups.  The SEM group was removed first using MgBr2•Et2O, followed by 
hydrogenolysis conditions to remove the Cbz group.  The free linear precursor was 
cyclized with HATU in 23% yield.  The Boc carbamate and TIPS ether were 
subsequently removed using HCl gas and the amine salt product of this reaction was 
coupled to the tamandarin B side chain using DEPBT to finish the synthesis of the natural 
product (Scheme 1.23). 
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Scheme 1.23: Completion of the total synthesis of tamandarin A and B. 
 
Along with the two natural products 56 and 57, two tamandarin A/didemnin hybrid 
analogs were synthesized and tested for biological activity.36 One of the analogs featured 
the tamandarin A macrocyclic core with the dehydrodidemnin B side chain, and the 
second analog featured the tamandarin A core along with the didemnin M side chain 
(Figure 1.10).  The biological activity of these analogs were compared to that of 
didemnin B and tamandarin B (Table 1.2). 
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Figure 1.10:  Two tamandarin A/didemnin natural product analogs (91 and 92) 
 
These compounds were submitted to the NCI-60 tumor cell screen for in vitro testing.  
The mean for all cell lines is shown in Table 2.  The cytotoxicity data shows that these 
compounds are all more potent than didemnin B, with the tamandarin 
A/dehydrodidemnin B (91) being the most potent, followed by analog 92, and tamandarin 
B (57).   
Table 1.2: Biological activity of selected compounds 
Compound GI50 LC50 
didemnin B 13 nM 3.8µΜ 
tamandarin B 2.3 nM 1.4 µM 
analog 91 1 nM 2.7 µΜ 
analog 92 4 nM 7.6 µΜ 
 
1.8) Other Synthetic Tamandarin B Analogs 
In 2006 Joullié and coworkers reported the synthesis of two tamandarin B macrocyclic 
analogs.37 The N,O-Me2Tyr5 residue was replaced with an N-MePhe residue in one 
analog and an N-MeNapth residue in the other (Figure 1.11).   
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Figure 1.11:  Two new tamandarin B macrocyclic analogs. 
 
The macrocycle of these two analogs were produced with different methods of 
cyclization.  Analog 93 was synthesized first using an approach similar to that of 
tamandarins A and B, cyclizing at the Nst1-Thr6 junction.  This cyclization went in low 
yield (16%).  However a different cyclization approach was employed with 94.  In this 
new cyclization, lactamization occurred at the Pro4-N,O-MePhe5 junction (Scheme 1.24). 
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Scheme 1.24:  Macrolactamization used in the synthesis of 94. 
 
This cyclization strategy worked significantly better than in the synthesis of the natural 
product macrocycle.  Not only was the cyclization yield higher, the use of two 
complimentary protecting groups (Bn and Cbz) made this sequence more efficient since 
they could be removed in one step.  The cytotoxicities of 93 and 94 were evaluated in a 
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panel of 14 tumor cell lines and compared to that of tamandarin B (57).  In general, these 
two analogs performed better than tamandarin B, with 95 and 96 showing similar 
cytotoxicity in vitro in the cell lines used.   These synthetic analogs showed that changes 
in the macrocyclic scaffold at position 5 with more lipophilic aromatic amino acids were 
well tolerated. 
In another study two more macrocyclic analogs were made (Figure 1.12), one was Ala4 
tamandarin B (97), and the second was Ser6 tamandarin B (98).38   
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Figure 1.12:  The structure of Ala4 tamandarin B and Ser6 tamandarin B. 
 
In this study, the macrocycles of 97 and 98 were made in the same way as 96.  The 
cytotoxicities of these compounds were evaluated in the same panel of 14 tumor cell lines 
as 94 and 95.  Changing from Thr6 to Ser6 resulted in minor changes in activity across the 
cell lines tested.  However changing Pro4 to Ala4 resulted in a dramatic loss of activity.  
This indicates that the proline residue is necessary for biological activity, whereas 
modifications at Thr6 can be moderately tolerated. 
 
1.9) Mechanism of Action 
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The mechanism of action of the tamandarin and didemnin families of natural products is 
poorly understood.  Even though these compounds have shown excellent biological 
activity, it is not clear how they work.  There have been two studies designed to identify 
potential target proteins.  In 1994 Crews and Shreiber made an affinity analog (99) of 
didemnin A by attaching a biotin tag of of the N-Me-D-Leu7 residue of the side chain 
(Gigure 1.13).39 This analog was made by semi-synthetic methods from the natural 
product. 
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Figure 1.13:  Biotinylated didemnin A. 
 
The protein isolated in the study was elongation factor 1α (EF-1α).  This protein is a 
common guanine nucleotide-binding protein that transports RNA to the ribosome.  The 
authors proposed a mechanism for protein biosynthesis inhibition in this report.  They 
conclude that didemnins bind to a GTP•EF-1α complex, which blocks RNA from 
interacting with the ribosome, hindering protein biosynthesis.  The proposed model for 
protein biosynthesis does not accout for the antiproliferative effects of the didemnins that 
occur at nanomolar concentrations.  The antiproliferative effect of didemnins on L-1210 
cells is highly dependent opon the configuration of the N-Me-Leu residue while protein 
inhibition potency is unaffected by this variable.  Therefore the potent antiproliferative 
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effect of this class of compounds is still unexplained.40 This study did not fully address 
the cytotoxic activity displayed by the didemnin family.  Since the didemnins show 
antitumor activity at significantly lower concentrations than protein biosynthesis 
inhibition, it is thought that this action happens by a different mechanism.   
In a later study Crews and Schreiber set out to isolate another didemnin binding protein 
using a different affinity ligand.41 In this study instead of using a biotin as a probe 
molecule, didemnin A was attached to a solid phase linker (100, figure 1.14).  The EF-1α 
was removed from the protein matrix using an anion exchange resin.  Next a 36 kD 
protein was isolated and identified as protein palmitoyl thioesterase (PPT1).  Mutations in 
the PPT gene have been linked to infantile neuronal ceroid lipofuscinosis (INCL), which 
is a degenerative brain disorder.  However, this finding still does not shed light on the 
didemnins as antitumor agents.  In a related study Toogood independently proved that 
inhibition of protein biosynthesis by didemnin B is not sufficient to induce apoptosis in 
MCF7 cells.42 
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Figure 1.14: Solid-phase linked didemnin A. 
 
A third study was initiated by Joullié and co-workers to design a different probe molecule 
to be used in the affinity studies.43,44 They synthesized Lys3 didemnin B (101, Figure 
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1.15).  The leucine residue was replaced with a lysine residue,  in which the exocyclic 
amino group would provide an alternate position to attach a biological probe.  The 
rationale behind this project was that didemnin A, which was used by Schreiber and 
Crews, is one of the least active didemnins, and the potency of this class of natural 
products is highly side chain dependent.  An attachment point far removed from the side 
chain would be optimal.  This analog showed greatly diminished antiproliferative activity 
compared to didemnin B, but its cytotoxicity was only moderately reduced. This analog 
was never used in an affinity study. 
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Figure 1.15:  Structure of Lys3 didemnin B. 
 
1.10) Conclusions 
A significant amount of effort has been devoted to the structure-activity relationships and 
the mechanism of action of the didemnins and tamandarins.  More side chain analogs of 
tamandarin B should be made to test whether the tamandarins are only didemnin mimics 
or individual therapeutic agents.  More importantly, the potent antiproliferative effect of 
these natural products need to be reexamined and explained. 
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Chapter 2 
 
2.1) Second-Generation Synthesis of the Tamandarin B Macrocycle  
 
Although tamandarin B had been synthesized, the low yielding cyclization of 1 caused 
difficulties in producing useful amounts of macrocycle 2 (Scheme 2.1).1 A new strategy 
that could afford a high-yielding cyclization would make the synthesis of the macrocycle 
more accessible and address a major problem of the first-generation synthesis.   
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Scheme 2.1:  First-generation approach towards the tamandarin B macrocycle 
 
Based on precedence from the tamandarin B macrocyclic analog synthesis2,3 and 
didemnin syntheses,4,5 the highest-yielding point of cyclization was expected to be at the 
Pro4-Me2Tyr5 junction.  This site had given superior yields of cyclized products over 
other possibilities to date.  This strategy is shown in Scheme 2.2. 
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Scheme 2.2: Second-generation approach to tamandarin B macrocycle. 
Another problem to address was the convergence of the synthesis.  In the first-generation 
synthesis two main fragments (Nst/Hiv (5) and tetrapeptide (6)) were synthesized and 
merged to form the linear precursor (Scheme 2.3).  Splitting the macrocycle into three 
fragments would make its synthesis more accessible and convergent by shortening the 
longest linear sequence.   
The last problem to address was the protecting group strategy.  One problem was the 
removal of an allyl group to form a carboxylic acid, a step that was low yielding and had 
to be carried on through another step as an impure mixture. Forming the free linear 
precursor before cyclization took two steps (Chapter 1, Scheme 1.23, pg. 30).  A 
protecting group strategy that allowed for a one step removal of the terminal protecting 
groups would make the synthesis more efficient.  The goal of a new protecting group 
strategy was to have quantitative removal of all protecting groups, so that the resulting 
product could be used without further purification. 
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Scheme 2.3:  Two-fragment approach to the tamandarin B macrocycle. 
 
With these requirements in hand, a second-generation retrosynthesis was proposed 
(Scheme 2.4).6 This strategy tried to address all of the issues mentioned above.   
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Scheme 2.4:  Second-generation retrosynthesis of tamandarin B macrocycle. 
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The first step of the retrosynthesis was opening the macrocycle (4) to form protected 
linear precursor 8.  This linear precursor was divided into three fragments.  The 
fragments were Hiv-Leu-Pro-OBn (9), Norstatine acid (10), and Tyr-Thr acid (11).  The 
terminal protecting groups of linear precursor 8 were benzyl ester and Cbz carbamate.  
These groups were chosen because they can be removed simultaneously under 
hydrogenolysis conditions.  The Hiv2 residue was incorporated into 9 to avoid the need to 
protect the secondary alcohol or acid functional groups.  In the first generation synthesis 
a Hiv-norstatine fragment required protecting group on the acid, which turned out to be 
problematic.  The protecting groups on the norstatine fragment 10 (TBS and Boc) could 
both be removed under acidic conditions simultaneously. 
The Hiv-Leu-Pro-OBn fragment (9) was synthesized first (Scheme 2.5).  The first step 
was coupling Pro-OBn•HCl (12) to Boc-Leu using diethylcyanophosphonate (DEPC).4 
This reagent gave a higher yield (99%) of the coupled product (13) compared to 
dicyclohexylcarbodiimide (DCC) (95%)2 or 4-(4,6-dimethoxy[1,3,5]triazi-2-
yl)methylmorpholinium chloride (DMTMM) (66%)7, which were used in the previous 
synthesis.  Next, the Boc group of 13 was removed under acidic conditions from the 
leucine nitrogen to form an HCl salt, which was directly coupled to 2S-hydroxyisovaleric 
acid (14) and used BOP to form alcohol 9 in 93% yield.  This was a significant 
improvement over the previous route in which this bond was formed using DCC (84%).2 
This fragment was made in three steps in an overall yield of 91%. 
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Scheme 2.5:  The synthesis of fragment 9. 
 
The next fragment to be synthesized was the norstatine fragment (10).  The first step was 
activation of N-Boc-D-valine (15) as its pentafluorophenylester (PfP) (16) using 
pentafluorophenyl trifluoroacetate (Scheme 2.6).  This activated ester was condensed 
with the lithium enolate of methyl acetate to form β-ketomethyl ester (17).  The ketone 
was then reduced using KBH4 to yield a β-hydroxymethyl ester (18) mixture of separable 
diastereomers (major product shown).  The resulting alcohol was protected as its TBS 
ether to yield 19.  Methyl ester hydrolysis using lithium hydroxide resulted in norstatine 
fragment 10.  A key feature to the synthesis of this fragment was the ability to separate 
the diastereomeric alcohols produced in the reduction step.  In previous syntheses1,2,7 the 
mixture of diastereomers (17 and epimeric alcohol) of this compound, or one where the 
Boc group is changed to Cbz, were carried through an additional step and separated after 
protection of the alcohol.  The synthesis of the norstatine fragment was completed five 
steps with an overall yield of 19%.   
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Scheme 2.6: Synthesis of norstatine fragment 10. 
 
The final fragment to be synthesized was the Tyr-Thr acid 11 (Scheme 2.7).  The first 
step was methylation of commercially available N-Cbz-L-Tyr (20) under basic 
conditions.  The resulting methyl ester was hydrolyzed in the same flask to yield acid 21.  
In a procedure similar to that in the Joullié synthesis of didemnin B macrocycle,8 acid 21 
was esterified with N-Boc-L-Thr-OSEM using isopropenyl chloroformate to yield 22.   
The SEM group was chosen because of its previous successful use in the synthesis of the 
didemnins and the first generation synthesis of tamandarins A and B.1,8  Unfortunately, 
the SEM group could not be removed under standard conditions (MgBr2•Et2O).9  The 
main product of this reaction was removal of the Boc group on the adjacent nitrogen. 
Switching to HF•pyridine to promote the removal of the SEM group did not result in any 
reaction.  The next reagents tried to facilitate this transformation were fluoride ion source 
(TAS-F10, TBAF on silica gel11).  These conditions also did not remove the SEM group. 
The conditions that were tried to effect this transformation and are summarized in Table 
2.1.   
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Scheme 2.7:  First attempt at the synthesis of 11. 
 
Table 1: Conditions screened to remove SEM group 
  Conditions Result 
MgBr2•Et2O, CH2Cl2 Removal of Boc group 
HF•pyridine No reaction 
TBAF on silica gel, THF No reaction 
TAS-F, DMF No reaction 
 
With these results in hand, it was determined that a different group was needed to protect 
the threonine carboxylate.  
An allyl group was used instead of the SEM group and the new target was 24 (Scheme 
2.8). 
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Scheme 2.8:  Change in protecting group strategy. 
 
The synthesis of 24 was completed by esterification of acid 20 with N-Boc-L-Thr-OAllyl  
(25) using EDCI.  Unfortunately isopropenyl chloroformate did not facilitate this 
transformation in high yield (~40%) with the switch in protecting group. 
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Scheme 2.9: Second attempt at the synthesis of 11. 
 
This new protecting group also presented problems.  The removal of this allyl group was 
not a highly scalable reaction.  On scales with less than ~100 mg of 24 this reaction went 
to completion in 6 h.  At larger scales, the rate slowed further and did not go to 
completion even after  3 days.  Adding higher loadings of catalyst or additional amounts 
of morpholine did not make the transformation more facile. If this protecting group was 
kept this step would become a bottleneck in the synthesis, so this group needed to be 
changed again.  The solution to this problem turned out to be replacing the allyl group 
with a methyl group.  The reason this group was not chosen first was that there were 
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concerns that the methyl ester could not be hydrolyzed without affecting the other ester 
present in this fragment.   
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Scheme 2.10:  New protecting group strategy. 
Using standard conditions to hydrolyze this ester such as lithium hydroxide would almost 
certainly hydrolyze the Tyr-Thr ester bond.  In 2007, Nicolaou reported a set of 
conditions to prevent this type of problem.12 He utilized trimethyltin hydroxide to 
selectively hydrolyze methyl esters in the presence of other esters.  The desired substrate 
(26) was made in a similar manner to 24.  First, acid 20 was subjected to an esterification 
reaction with N-Boc-Thr-OMe (27) using EDCI mediated conditions to form 26. Next, 
treatment of 26 with trimethyltin hydroxide in 1,2-dichloroethane, at 70 °C under 
microwave conditions cleanly yielded desired acid 11 in quantitative yield, and in 3 h.   
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Scheme 2.11: The synthesis of 11. 
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With all three desired fragments in hand, the next step was to assemble the linear 
precursor (8).  The first step of the sequence was an esterification reaction of acid 10 and 
alcohol 9.  Using EDCI and DMAP to promote this reaction led to reaction yields of 
<20% of the product (28).  Using DCC instead of EDC resulted in a similar result.   
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Scheme 2.12: Initial attempts at formation of 28. 
 
Changing from a carbodiimide-based reagent to a chloroformate (isopropenyl 
chloroformate or isobutylchloroformate) in order to go through a mixed anhydride 
intermediate also gave similar results (Table 2.2).  
 
Table 2.2: Esterification conditions 
Condition Yield of 28 (%) Yield of 29 (%) 
EDCI, DMAP, THF 20 40 
DCC, DMAP, CH2Cl2 18 45 
Isopropenyl chloroformate, 
DMAP, Et3N, CH2Cl2 
15 34 
Isobutyl chloroformate, 
DMAP, Et3N, CH2Cl2 
13 31 
 
 The problem with this reaction was an undesired side-product, which formed in higher 
yield than the desired product.  This side product turned out to be lactam 29, which was 
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the cyclized product of the activated intermediate of acid 10.  This problem was also 
observed by the Joullié group in the first generation synthesis of tamandarins A and B1 on 
a similar substrate, and a low yield for the same reaction was observed in an analog 
synthesis.2 After these initial investigations, it became obvious that this problem was due 
to the substrate and a modification to the norstatine acid was necessary.  The problem that 
had to be addressed was the nucleophilicity of the Boc protected nitrogen.  The 
nucleophilicity had to be suppressed or blocked completely.  The simplest solutions 
would be either bis-protection (such as two Boc groups, 30) or to tie the nitrogen back 
into the ring (31) (Figure 2.1).  
O
OH
O
BocN
NBoc2
OH
OTBSO
30                                           31  
Figure 1: Possible solutions to block nitrogen nucleophilicity. 
 
 With those two ideas in mind, the easiest thing to do was to form a five-membered ring 
with the neighboring alcohol in the form of an N,O-isopropylidene acetal.  This solution 
seemed to be the best because the route to the norstatine fragment starting from D-valine. 
would not have to be completely modified.  Also, instead of protecting alcohol 18 as its 
TBS ether, the five-membered ring could be formed at that point.  To execute this step 
the first conditions tried were similar to those used by Jouin in the synthesis of 
nordidemnin B.13 These conditions consisted of heating the alcohol to reflux in 2,2-
dimethoxy propane and acetone in the presence of catalytic BF3•Et2O.  Unfortunately 
these conditions only gave a 35% yield of the product along with lactam 29.  Lowering 
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the temperature to room temperature or changing to PTSA did not give higher yields of 
the products.  The final solution was to use stoichiometric (±)-10-camphorsulfonic acid in 
2,2-dimethoxypropane and acetone at room temperature to form the desired N,O acetal in 
56% yield (Scheme 2.13).  The methyl ester was then hydrolyzed with lithium hydroxide 
in quantitative yield.   
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Scheme 2.13: Synthesis of acid 31. 
 
With acid 31 in hand, esterification with alcohol 9 afforded a 94% yield using the original 
conditions of EDC and DMAP.  The undesired lactam 29 was not formed under these 
conditions. 
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Scheme 2.14:  Synthesis of 33. 
 
Upon finding a reliable way to get to compound 33, the next steps involved removing the 
Boc group, fragmenting the N,O acetal, and coupling the resulting HCl salt to acid 11 to 
form the linear precursor (8).  The first step was done by converting compound 33 to the 
HCl salt by treating it with 4.0 M hydrogen chloride in dioxane.  After two hours both 
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protecting groups were removed under the acidic conditions.  The salt was then directly 
coupled to acid 11 using BOP and iPr2NEt in 76% yield (Scheme 2.15). 
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Scheme 2.15: Synthesis of linear precursor 8. 
 
With linear precursor 8 in hand, the next step was to remove both the Cbz and benzyl- 
protecting groups.  Initial attempts at removing these two groups revolved around the use 
of 10% Pd/C.  At ambient temperature and 1 atm pressure this reaction took 2 days to go 
to completion.  The reaction was then conducted at 45 psi using a Parr hydrogenator.  
This resulted in faster reaction times of 4 h, but the yield dropped from quantitative to 
80%.  Replacing 10% Pd/C with 10% Pd(OH)2/C shortened reaction times to 10 h, and 
could be done at 1 atm pressure (Scheme 2.16).  Attention was then turned to 
macrocyclization.  The initial conditions tried were those used by Shioiri in his didemnin 
B synthesis4 because of the high yields achieved in the synthesis of the didemnin B 
macrocycle.  The exact conditions used were BOPCl as the coupling reagent in the 
presence of Et3N in CH2Cl2 at 1 mM concentration. Unfortunately, our yield was 
nowhere near what Shioiri (18% vs. 76%) had obtained.  The significant decrease in yield 
could be attributed to the difference in the linear precursor.  The first major difference 
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was the ring size.  The didemnins possessed a 23-membered ring while tamandarin B 
only had a 21-membered ring.  The second difference was how the two molecules were 
functionalized. Shioiri protected the alcohol of the norstatine as its TBS ether.  He also 
had the Me-Leu7 residue of the side chain in place before cyclization.  In the route to the 
tamandarin B, the Thr6 residue was Boc protected and the Me-Leu7 was not present. The 
next set of conditions tried were similar to those used by Giralt in his synthesis of 
dehydrodidemnin B.5 These conditions used HATU, HOAt, and iPr2NEt in CH3CN.  
Using this protocol in our system gave a  24% yield (compared to 76% for Giralt).  The 
only differences in the two systems was the ring size and dilution.  Giralt also had the 
norstatine alcohol unprotected and the Thr6 protected as a Boc group. Our reaction was 
done at 1 mM concentrations.  In Giralt’s report the reaction was done in 35 µL (1.15 M) 
of THF, which seemed to be too concentrated for a cyclization .  Adrio and Joullié also 
used these conditions. The next set of conditions that were tried were DMTMM, NMM in 
acetonitrile.14 This set only gave a yield of 20%.  After this result T3P, iPr2NEt, CH2Cl2 
were investigated.15 These conditions gave a yield of 30%, which was the highest, but 
still not optimal.  Finally the conditions that best facilitated this transformation were 
PyAOP16,17 and NMM in DMF at a 1 mM concentration for 48 h.  These conditions gave 
a yield of 49% of the desired macrocycle.  Most importantly, this reaction proved to be 
highly scalable and easily purified.  All of the results of the macrocyclization are 
summarized in Table 2.3. 
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Scheme 2.16: Formation of macrocycle 2. 
 
Table 2.3: Optimization of macrocyclization. 
 
The second-generation synthesis of the tamandarin B macrocycle was completed in a 
longest linear sequence of 10 steps and a 6.6% overall yield.  This was a significant 
improvement.  The original synthesis was 12 steps and gave an overall yield of 3.2%.  
This second-generation synthetic route was two synthetic steps shorter than the first and 
almost doubled the yield. 6  
2.2)  Synthesis of Three Tamandarin B/Didemnin Hybrid Analogs 
With a reliable route to the tamandarin B macrocycle, attention was turned to 
synthesizing analogs with the tamandarin B macrocycle and assorted didemnin side 
chains, to determine if these hybrid analogs would maintain biological activity.   The 
natural product didemnin M,18 dehydrodidemnin B,5,19 and Ψ[CH2NH] didemnin B20 
Reagent Base Solvent Concentration Yield (%) 
BOPCl Et3N CH2Cl2 0.001M 18 
HATU iPr2NEt THF 0.001M 23 
HATU NMM CH3CN 0.001M 25 
DMTMM NMM CH3CN 0.05M 20 
T3P® iPr2NEt CH2Cl2 0.00075M 30 
PyAOP NMM DMF 0.001M 49 
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(discussed in Chapter 1) are potent molecules with interesting biological activity.  The 
analogs containing the tamandarin A/didemnin M21 side-chain and tamandarin 
A/dehydrodidemnin B1 side-chain were also made.  In vitro testing of these molecules 
has shown similar activity to that of the parent natural products.  The tamandarin B 
versions of these compounds have never been made.  It would be advantageous to 
synthesize these compounds for several reasons.  For instance, with the new route to the 
tamandarin B macrocycle accessing these compounds in useful amounts should be 
straightforward.  The second reason was that the tamandarin B macrocycle did not 
contain the unnatural D-alloisoleucine, which is expensive or takes several additional 
synthetic steps to make.  Ease of synthesis and more affordable starting materials makes 
the tamandarin B analogs of these molecules more attractive targets (Figure 2.2).  This 
study would also help determine the effects of side chain structure on the biological 
activity of tamandarin B and could produce compounds with potential therapeutic value.  
The strategy behind the retrosynthetic approach was to selectively couple the side chain 
to the macrocyclic amine salt as the final step in their synthesis. 
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Figure 2.2: Structure of tamandarin B/didemnin hybrid analogs. 
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2.3) Previous Routes to Side Chains 
 
The selected side chains were made previously by Joullié and co-workers.1,20,21 These 
side chain acids were made by three different routes each having a different strategy.  The 
dehydrodidemnin B side chain and didemnin M side chains were made in a similar 
fashion.  The synthesis began with known acid 37, which was coupled to N-Me-D-Leu-
OMe using BOP-Cl to yield methyl ester 38.  Hydrogenolysis conditions removed the 
benzyl ether to yield 39.  At this point the synthesis of the two side chains diverged from 
this common intermediate.  To make the dehydrodidemnin B side chain, Dess-Martin 
oxidation22 yielded the fully functionalized side chain 39 (Scheme 2.17).  Subsequent 
hydrolysis yielded the free acid side chain (40).  
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Scheme 2.17: First generation approach to dehydrodidemnin B side chain. 
 
The didemnin M side chain was made by first converting the methyl ester 39 to benzyl 
ester 41. Esterification of this alcohol with BocGlu(Xan)OH using DCC yielded 
compound 42.21 Removal of the Boc and xanthyl groups with HCl gas yielded an amine 
salt, which was condensed with N-Cbz-p-Glu-OPfP to yield the fully functionalized side 
chain.  Removal of the Cbz and benzyl groups resulted in the didemnin M free acid side 
chain (43, Scheme 2.18). 
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Scheme 2.18:  Synthesis of the tamandarin M side chain. 
 
The Ψ[CH2NH] didemnin B side chain was constructed in a slightly different manner 
than 40 and 43.20 The key step in its synthesis was the reductive amination of aldehyde 
44 and amine 45 in the presence of Na(OAc)3BH and AcOH to yield 46.  Removal of the 
Boc group and coupling the resulting salt to L-lactic acid yielded the fully functionalized 
side chain (47), which after hydrogenolysis gave the free acid side chain (48, Scheme 
2.19).  
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Scheme 2.19:  Synthesis of Ψ[CH2NH] didemnin B side chain. 
 
2.4)  New Routes to Didemnin Side Chains 
With these routes in mind, we developed a unified approach for making the side chains, 
which allowed the production of these acids from as many common intermediates as 
possible.  Another problem to be addressed in the synthesis of the didemnin M side chain 
was the protecting group strategy.  Optimally one would  use as few protecting groups as 
possible, and choose groups that could be carried out through the whole synthesis, and 
not have to be exchanged.  With respect to the Ψ[CH2NH] side chain, this route could be 
only moderately improved, but two ways to improve it would be by shortening the route 
to N-Boc-prolinal (44) from four steps to two steps and by screening different conditions 
for the reductive amination product.  The strategy chosen is shown in Scheme 2.20. The 
three starting materials (amine 45, N-Boc-L-proline (49), and L-lactic acid (50)) could be 
used in the synthesis of all three side chains and permit minimal protecting group use. 
This approach would also allow the common intermediates to be used in the preparation 
of all three acids. 
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Scheme 2.20:  New approach to 40, 43 and 48.   
 
2.5) Synthesis of Dehydrotamandarin B  
 
The synthesis started with the protection of L-leucine (51) as its Boc carbamate.  Benzyl 
ester formation23 followed by N-methylation with NaHMDS and MeI yielded 52.  
Removal of the Boc group under acidic conditions yielded  a hydrochloride salt, which 
was directly coupled to Boc-Proline (49) using BOPCl in excellent yield.  Next, removal 
of the Boc group using HCl yielded a salt, which was then directly coupled to lactic acid 
(50) using BOP to yield 41.  The next step was to oxidize the secondary alcohol to the 
ketone.  Using the original Joullié conditions of Dess-Martin periodinane only gave low 
yields (~50%).1 Adding Na2CO3 to the reaction further decreased the yields (35%).  The 
conditions that gave the best yields were Dess-Martin periodinane in CH2Cl2/DMSO 
(9:1) that gave the product (54) in good yield.  Hydrogenolysis of the benzyl ester 
resulted in free acid 40 (Scheme 2.21).  The synthesis of 40 was completed in in 9 total 
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steps.  The previous synthesis by the Joullié group was 11 total steps.1 This route has a 
two-step improvement over the previous method. 
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Scheme 2.21:  Synthesis of dehydrodidemnin B side chain. 
The free acid was coupled to the freshly prepared amine salt of the tamandarin B 
macrocycle to form the tamandarin B/dehydrodidemnin B hybrid (dehydrotamandarin B) 
(Scheme 2.22).24 
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Scheme 2.22:  Completion of dehydrotamandarin B. 
 
2.6) Synthesis of Tamandarin M 
The next target was the didemnin M side chain.  Intermediate 41 was used as the starting 
point.  This alcohol was esterified with freshly prepared BocGlu(Xan)OH25 using EDCI 
to form 42.  Removal of the Boc and xanthyl groups was accomplished using HCl gas to 
form the hydrochloride salt, which was immediately condensed with N-Cbz-pGluOPfP to 
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form the fully functionalized side chain.  Exposure to hydrogenolysis conditions removed 
the Cbz and benzyl groups to form the free acid side chain 43 (Scheme 2.23). This 
method was similar to that used previously in the Joullié group.  The main difference was 
a linear synthesis to 41, which made the synthesis more convergent with acid 40.  A 
minor difference was the use of EDCI instead of DCC to form 42.  This change allowed 
for a more simplified workup and purification. 
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Scheme 2.23:  Synthesis of the didemnin M side chain. 
 
The synthesis of the tamandarin B/didemnin M hybrid (Tamandarin M) was completed in 
a similar manner to that of dehydrotamandarin B.  The Boc protected tamandarin B 
macrocycle (2) was treated with HCl to form the amine salt, which was then coupled to 
acid 43 to form tamandarin M (Scheme 2.24).24 This coupling afforded the product in 
81% yield, which was a great improvement over the 32% obtained in the same reaction 
with the tamandarin A macrocyclic salt.21 
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Scheme 2.24: Synthesis of tamandarin M. 
 
2.7) The Synthesis of Ψ[CH2NH] Tamandarin B 
 
The final acid to be synthesized was the Ψ[CH2NH] didemnin B side chain (48).  The 
starting material for this acid was N-Me-D-Leu-OBn (salt of this used above) and an 
electrophile adapted from Boc-Pro.  While it was known from previous work from the 
Joullié group that reductive amination using Na(OAc)3BH would facilitate this 
transformation,  two other methods were screened to see if they would give better results.  
The first was displacement of an alkyl iodide with an amine nucleophile (Scheme 2.25).  
This method was reported to give excellent yields of amide surrogates of this type.  Boc-
Prolinol (54) was iodinated to form 55 and subjected to the amine (56) and Cs2CO3 in 
DMF.26 Unfortunately this procedure only yielded minimal amounts of the desired 
product (<10%).  
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Scheme 2.25:  Alternative conditions to form 57. 
 
Attention was then turned to reductive amination conditions.  In order to address these 
conditions, a better route was needed to N-Boc Prolinal.  The previous route began by 
methylating L-proline and protecting the amine as its Boc carbamate.  Next, the methyl 
ester was reduced to the alcohol using lithium borohydride, and finally oxidized to the 
aldehyde using SO3•pyridine (Scheme 2.26).20 The synthesis of this compound was made 
in two steps starting from Boc-Proline.  One possible method to accomplish this was by 
reducing Boc-Pro-OMe using DIBAL to form the aldehyde.  While this approach did 
work, the highest yielding method to make this aldehyde was by borane reduction and 
Swern oxidation (Scheme 2.26).27,28 This revised route gave a yield of 86% over the two 
steps, while the previous route gives a 54% yield over four steps. 
Previous                                                                                         Revised
N
H
O
OH
1) SOCl2, MeOH, !, 91%
2) Boc2O, Et3N,CH2Cl2, 85%
3) NaBH4, LiCl, MeOH, 85%
4) SO3•pyr, 81%
N
Boc
O
H N
Boc
O
OH
1) BH3•DMS, THF, 91%
2) (COCl)2, DMSO,  then
     iPr2NEt, CH2Cl2, 95% NBoc
O
H
49                                                                           4458                                                                         44  
Scheme 2.26: Different routes to Boc-prolinal. 
The first set of reductive amination conditions tried used 5-ethyl-2-methyl-pyridine 
borane (PEMB) as the reducing agent.29 This reagent gave modest yields (35%) and 
reactions often did not go to completion (Scheme 2.27).  Unable to get other conditions to 
work, the reductive amination conditions similar to those used previously were applied.  
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Using Na(OAc)3BH as the reducing agent with stoichiometric acetic acid gave the 
desired product in acceptable yield (65%) in 3 hours.30 An important aspect of this 
reaction was that the HCl salt of 56 did not react nearly as well as the free base.  
Reductive aminations with the HCl salt only afforded in 23% yield.  Generating the free 
amine in situ using Et3N did not resolve this problem. It was necessary to use 56 as the 
free amine to obtain acceptable yields.  With these results the same steps were taken as in 
Scheme 2.19 to complete the synthesis of this acid.  This acid was coupled to the 
macrocyclic salt of 2 as shown in Scheme 2.27 to form 36.  In the synthesis of this analog 
HATU was used to couple the side chain to the macrocyclic salt instead of BOP.  This 
reagent gave higher yields and a pure product after aqueous workup.24   
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Scheme 2.27:  Synthesis of Ψ[CH2NH] tamandarin B. 
 
2.8) Biological Testing 
Compounds 34, 35, and 36 were submitted and tested in the NCI-60 tumor cell screen.  
Dehydrotamandarin B (35) performed well in the cell based assays with GI50 values of 
less than 10 nM in 23 of the 60 cell lines tested along with LC50 values greater than 1µM 
in 55 of the 60 cell lines tested.  Ψ[CH2NH] Tamandarin B (36) tested similarly as 35 
with GI50 values less than 10 nM in 28 of the 60 cell lines, and had LC50 values of greater 
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than 1 µM in 48 of the 60 cell lines tested.  Tamandarin M (34) was the  most potent in 
these tests.  It displayed GI50 values of less than 10 nM in all of the cell lines tested and 
LC50 values of greater than 1 µM in 45 of the 60 cell lines.  To get a better handle on the 
biological activity, a collaboration was started with Professor Craig Crews at Yale 
University.  His lab tested compounds 34 and 35 for activity in HeLa cells and for 
immunosuppressive reactivity via mixed lymphocite reaction.  Analog 35 displayed an 
IC50 of 0.608 nM in HeLa cells.  It gave an IC50 of 0.765 nM in the mixed lymphocite 
reaction.  Analog 34 showed extremely potent activity in both assays.  In HeLa cells it 
displayed an IC50 of 0.851 fM and an IC50 of 1.78 fM in the mixed lymphocite reaction.  
With these impressive results, the fragments of tamandarin M (34) were tested for 
activity in HeLa cells.  The fragments tested were the macrocyclic salt (59) and free acid 
side chain 43 (Figure 2.3).  While 59 was inactive, 43 showed good activity with an IC50 
of 0.385 nM. 
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Figure 3: Fragment biological activity. 
 
2.9) Conclusions 
Significant improvements have been made to the synthesis of the tamandarin B 
macrocycle.  The number of steps has been reduced and the yield has been doubled.  This 
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was important for the production of the analogs discussed above.  Side chain acids 40, 43, 
and 48 were made in a manner where common intermediates from each could be used to 
produce all three.  The biological activity of these three analogs was impressive in vitro.  
While these results are encouraging it is unclear if any of these compounds could be 
potential therapeutic reagents until further studies are done.  Also the source of biological 
activity is still unclear since a mechanism of action of this class of natural products is still 
not elucidated. 
2.10) Experimental Results 
 
General Methods. All reactions were carried out under an argon atmosphere.  
Tetrahydrofuran was distilled over sodium benzophenone. Dichloromethane and 
methanol were distilled over calcium hydride prior to use.  Column chromatography was 
conducted using silica gel 60 (240-400 mesh) and solvent systems are listed under 
individual experiments.  Analytical thin-layer chromatography (TLC) was performed on 
silica gel (60F-254) plates (0.25mm).  Plates were visualized using ceric ammonium 
molybdate, phosphomolybdic acid or ninhydrin.  Proton and carbon magnetic resonance 
spectra were recorded on a 500 MHz spectrometer at 500 MHz and 125 MHz 
respectively.   
General procedure for removal of benzyl and Cbz groups.  The desired substrate was 
dissolved in a 1:1 mixture of anhydrous MeOH/EtOAc (0.1 M).  To this solution was 
added 10% Pd/C (10% wt).  The reaction was monitored by TLC and was filtered 
through a pad of Celite when complete.  Removal of solvent under reduced pressure 
provided the product, which was used without further purification. 
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N-Boc-Leu-Pro-OBn (13).  Proline benzyl ester hydrochloride 
(115 mg, 0.48 mmol) and Boc-leucine (100 mg, 0.43 mmol) 
were dissolved in anhydrous DMF (3 mL) and cooled to 0 °C.  
To this solution was added DEPC (72µL, 0.48 mmol) and 
triethylamine (120 µL, 0.86 mmol).  The reaction was allowed to warm to room 
temperature and stir overnight.  The mixture was diluted with ethyl acetate (15 mL) and 
washed with 10% citric acid (10 mL), saturated NaHCO3 (10 mL), water (10 mL) and 
brine (10 mL).  The organic layer was dried over Na2SO4, filtered, and concentrated.  
Purification by column chromatography (10% acetone/hexanes) led to the product as a 
yellow oil (178 mg, 98%).   Rf 0.32 (30% acetone/hexanes); 1H NMR (500 MHz, CDCl3) 
δ 0.82 (d, J=6.7 Hz, 3H), 0.88 (d, J=6.5 Hz, 3H), 1.34 (s, 9H), 1.66 (septet, J=6.7 Hz, 
1H), 1.92 (m, 3H), 2.12 (m, 2H), 3.50 (m, 1H), 3.68 (q, J=9.2 Hz, 1H), 4.38 (q, J=7.6 Hz, 
1H), 4.50 (dd, J=8.5, 3.9 Hz, 1H), 4.59 (s, 1H), 5.05 (m, 1H), 5.10 (m, 2H), 7.25 (m, 5H); 
13C NMR (125 MHz, CDCl3) δ 21.9, 23.6, 24.8, 25.1, 29.2, 42.2, 46.9, 50.5, 65.2, 67.1, 
79.7, 127.2, 127.6, 127.6, 128.5, 128.6, 135.8, 141.6, 156.0, 172.1; IR (cm-1) 3311, 2958, 
2871, 1745, 1708, 1647, 1499, 1437, 1168; ΗRMS (ESI) m/z calculated for 
C23H34N2O5Na (M + Na)+: 441.2366, found: 441.2355; 
! 
"[ ]D
21.659.97 (c  0.90, CHCl3). 
 
Hiv-Leu-Pro-OBn (9). N-Boc-Leu-Pro-OBn (100 mg, 0.24 
mmol) was dissolved in 4.0 M HCl in dioxane (3 mL) and the 
solution allowed to stir at room temperature for 3 h at which 
point the reaction solvent was removed to yield the salt as a 
white solid, which was used without futher purification.  The 
N
O
OBn
O
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O
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salt (94 mg, 0.24 mmol) was dissolved in anhydrous dichloromethane (1 mL) and cooled 
to 0 °C.  To this was added hydroxyisovaleric acid 14 (33mg, 0.28 mmol), NMM (66 µL, 
0.59 mmol), and BOP (116 mg, 0.26 mmol).  The reaction was allowed to warm to room 
temperature and stir overnight.  The mixture was diluted with ethyl acetate (20 mL) and 
washed with 10% HCl (10 mL), saturated NaHCO3 (10 mL), and brine (10 mL).  The 
organic layer was dried over Na2SO4, filtered and concentrated to yield the crude product.  
This compound was purified by column chromatography (2040% acetone/hexanes) to 
yield the product as a yellow oil (101 mg, quantitative). Rf 0.36 (30% acetone/hexanes); 
1H NMR: (500 MHz, CDCl3) δ 0.81 (d, J=6.45 Hz, 3H), 0.89 (m, 6H), 0.97 (d, J=6.55 
Hz, 3H), 1.45 (t, J=9.69 Hz, 1H), 1.57 (t, J=9.99 Hz, 1H), 1.65 (m, 1H), 1.99 (m, 3H), 
2.17 (m, 3H), 3.58 (d, J=7.70 Hz, 1H), 3.76-3.79 (m, 1H), 3.93 (s, 1H), 4.50 (s, 1H), 4.76 
(m, 1H), 5.03-5.15 (m, 2H), 7.31 (m, 5H); 13C NMR: (125 MHz, CDCl3) δ 15.5, 19.2, 
21.6, 23.3, 24.6, 24.8, 28.9, 31.6, 40.8, 46.9, 48.4, 59.0, 66.9, 75.9, 128.1, 128.3, 128.5, 
135.5, 171.5, 172.0, 175.9; IR (cm -1): 3382, 2960, 2873, 1745, 1639, 1520, 1454, 1260, 
1173, 1261; ΗRMS (ESI) m/z calculated for C23H34N2O5Na (M + Na)+: 441.2365, found: 
441.2359; 
! 
"[ ]D
23.6 -91.71 (c  0.60, CH2Cl2). 
N-Boc-D-Val-OPfP. Boc-D-Valine (8.41 g, 38.70 mmol) was 
dissolved in anhydrous dichloromethane (97 mL) and cooled to 0 
°C.  To this solution was added distilled pyridine (3.42 mL, 42.8 
mmol) and pentafluorophenyl trifluoroacetate (13) (8.0 mL, 46.4 mmol).  The reaction 
was allowed to warm to room temperature and stir overnight.  The reaction was quenched 
with saturated NH4Cl and allowed to stir for 15 minutes.  The mixture was diluted with 
dichloromethane (30 mL) and the layers were separated.  The organic layer was washed 
O
OPfP
NHBoc
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with 10% KHSO4 (20 mL), saturated NaHCO3 (20 mL), and brine (20 mL).  The organic 
layer was dried over MgSO4, filtered and concentrated to yield the product as an oil that 
eventually formed a white solid upon standing.  The white solid was used without further 
purification (13.01 g, 87%). 
β-Ketoester (17). n-Butyllithium (52.0 mL, 130.69 mmol, 2.5 
M in hexanes) was added to distilled diisopropylamine (18.0 
mL, 130.69 mmol) in anhydrous tetrahydrofuran (70 mL) at 0 
°C and allowed to stir for 30 minutes at which time it was cooled to -78 °C. Methyl 
acetate (10.4 mL, 130.69 mmol) was added dropwise to this solution to form the lithium 
enolate.  The mixture was stirred for 1 h.  In a separate flask PfP ester 14 (11.65 g, 30.39 
mmol) was dissolved in anhydrous tetrahydrofuran (98 mL) and cooled to -78 °C.  The 
PfP ester solution was transferred to the lithium enolate solution via cannula.  The 
reaction was allowed to stir at -78°C for 3 h at which time the cooling bath was removed 
and the reaction was quenched with saturated NH4Cl (40 mL).  The mixture was allowed 
to warm to room temperature and is diluted with dichloromethane (100 mL).  The organic 
layer was washed with 10% HCl (40 mL), saturated NaHCO3 (40 mL), and brine (40 
mL).  The organic layer was dried over Na2SO4, filtered, and evaporated to yield the 
crude product as an orange oil.  Purification by column chromatography (51015% 
EtOAc/hexanes) yielded the product as a yellow oil (6.86 g, 83%). Rf 0.56 (30% 
EtOAc/Hexanes); 1H NMR: (500 MHz, CDCl3) δ 0.77-1.03 (m, 6H), 1.43 (s, 9H), 2.22 
(m, 1H), 3.56 (s, 2H), 3.73 (s, 3H), 4.30 (s, 1H), 5.02 (d, J=7.03 Hz, 1H); 13C NMR: (125 
MHz, CDCl3) δ 17.6, 19.7, 28.3, 29.5, 46.9, 52.4, 64.3, 80.0, 158.8, 167.1, 202.0; IR (cm 
O
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-1):  3373, 2933, 2967, 1748, 1715, 1643, 1367, 1170, 1019; HRMS (ESI) m/z calculated 
for C13H23NO5Na (M +Na)+: 296.1474, found: 296.1486; 
! 
"[ ]D
21.1 15.94 (c  2.0, CHCl3). 
β-Hydroxyester (18). β-Ketoester 15 (6.86 g, 25.10 mmol) was 
dissolved in anhydrous methanol (251 mL) and cooled to -78 
°C.  To this solution was added potassium borohydride (4.74 g, 
87.84 mmol) and the reaction stirred at -78 °C for 20 minutes. The temperature was then 
raised to -20 °C for an additional 1 h.  The cooling bath was removed and glacial acetic 
acid (3 mL) was added and the mixture was allowed to stir until all solids dissolved.  The 
solvent was evaporated and the remaining residue was dissolved in EtOAc/H2O (1:1, 100 
mL).  The organic layer was separated and dried over Na2SO4, filtered, and concentrated 
to yield the crude product.  Purification by column chromatography (540% 
EtOAc/hexanes) afforded the product as a white solid (3.65 g, 53%). Rf 0.34 (30% 
EtOAc/hexanes); 1H NMR: (500 MHz, CDCl3) δ 0.85 (d, J=6.80 Hz, 3H), 0.91 (d, 
J=6.85 Hz, 3H), 1.41 (s, 9H), 2.08 (m, 1H), 2.45 (dd, J=16.3, 9.0 Hz, 1H), 2.45 (dd, 
J=16.3, 2.25 Hz, 1H), 3.25 (d, J=4.95 Hz, 1H), 3.49 (m, 1H), 3.68 (s, 3H), 3.89 (s, 1H), 
4.41 (d, J=9.64 Hz, 1H); 13C NMR: (125 MHz, CDCl3) δ 16.2, 20.1, 27.5, 28.3, 38.2, 
51.9, 58.8, 79.5, 156.4, 173.6; IR (cm -1): 3450, 3370, 2964, 1718, 1694, 1524, 1367, 
1172; HRMS (ESI) m/z calculated for C13H25NO5Na (M + Na)+: 298.1631, found: 
298.1630; 
! 
"[ ]D
21.1 -4.16 (c  0.75, CH2Cl2). 
N-Boc-Thr-OMe (27). N-Boc-Thr (100 mg, 0.46 mmol) was 
dissolved in anhydrous DMF (2 mL).  To this was added methyl 
iodide (57 µL, 0.91 mmol) and sodium carbonate (145 mg, 1.37 
O
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O
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mmol).  The reaction was allowed to stir overnight then was diluted with ethyl acetate (20 
mL) and washed with water (2 x 10 mL), 10% HCl (10 mL), and brine.  The organic 
layer was dried over Na2SO4, filtered, and concentrated to yield the product, which was 
used without any further purification (92 mg, 86%). Rf 0.26 (30% EtOAc/hexanes); 1H 
NMR (500 MHz, CDCl3) δ 1.25 (d, J=6.36Hz, 1.46 (s, 9H), 1.93 (s, 9H), 3.78 (s, 3H), 
4.28 (m, 2H) 5.27 (bs, 1H); 13C NMR: (125 MHz, CDCl3) δ 14.1, 19.8, 28.2, 52.3, 58.7, 
60.3, 80.0, 156.1, 171.9; IR (cm -1): 3436, 2979, 2935, 1744, 1718, 1510, 1368, 1167; 
HRMS (ESI) m/z calculated for C10H19NO5Na (M + Na)+: 256.1161; found: 256.1162; 
! 
"[ ]D
21.4  -8.77 (c  0.75, CH2Cl2). 
Cbz-N,O-Dimethyltyrosine-O-Boc-threonine-OMe (26). 
Cbz-N,O-Dimethyltyrosine (176 mg, 0.51 mmol) and N-Boc-
Thr-OMe (27) (92 mg, 0.39 mmol) were dissolved in 
anhydrous tetrahydrofuran (4.5 mL) and cooled to 0 °C.  To 
this was added EDCI (98 mg, 0.51 mmol) and DMAP (96 
mg, 0.79 mmol) The reaction was allowed to warm to room 
temperature and stir for 24 h.  The reaction was diluted with ethyl acetate (20 mL) and 
washed with 10% HCl (10 mL), saturated NaHCO3 (10 mL), and brine (10 mL).  The 
organic layer was dried over Na2SO4, filtered and concentrated to yield the crude product.  
Purification by column chromatography (20% ethyl acetate/hexanes) yielded the product 
as an oil (202 mg, 92%). Rf 0.50 (30% acetone/hexanes); 1H NMR: (500 MHz, CDCl3) 
δ 1.25 (m, 3H), 1.43 (s, 9H), 2.75 (m, 3H), 2.83-2.97 (m, 1H), 3.17 (m, 1H), 3.67 (m, 
3H), 3.75 (s, 3H), 4.42 (s, 1H), 4.75 (d, J=6.03 Hz, 1H), 5.03-5.11 (m, 2H), 5.25 (d, 
J=9.05 Hz, 1H), 5.39 (s, 1H), 6.77 (d, J=7.80 Hz, 2H), 6.95-7.10 (m, 2H), 7.29 (m, 5H); 
OMe
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13C NMR (125 MHz, CDCl3) δ 16.9, 28.2, 31.9, 34.1, 52.5, 55.1, 56.9, 60.4, 67.3, 71.6, 
80.2, 113.9, 127.5, 127.6, 127.8, 127.9, 128.4, 128.8, 129.7, 129.8, 136.6, 155.9, 156.4, 
158.3, 169.8, 170.4; IR (cm -1): 3350, 2978, 1746, 1712, 1514, 1248, 1166; HRMS (ESI) 
m/z Calculated for C29H38N2O9Na (M+Na)+: 581.2475, found: 581.2475; 
! 
"[ ]D
22.0 -13.90 (c  
0.9, CH2Cl2). 
Cbz-N,O-Dimethyltyrosine-O-Boc-threonine-OH (11). 
Methyl ester 20 (279 mg, 50 mmol) was dissolved in 
anhydrous 1,2 dichloroethane (5.6 mL) in a microwave 
reactor tube.  To this was added trimethyltin hydroxide (361 
mg, 200 mmol) and the reaction vessel was heated in a 
microwave reactor (3 h, 70 °C, 100 W).  The solvent was evaporated and the remaining 
residue was dissolved in ethyl acetate (20 mL).  This solution was washed with 10% 
KHSO4 (10 mL) and brine (10 mL).  The organic layer was dried over Na2SO4, filtered 
and concentrated to yield the product as a white solid which was used without any further 
purification (268 mg, 99%). 
Oxazolidine methyl ester (32). β-Hydroxy ester 16 (2.01g, 
7.3 mmol) was dissolved in acetone (18.5 mL) and 2,2-
dimethoxypropane ( 18.5 mL).  To this solution was added 10 
(±)-camphorsulfonic acid (1.69g, 7.3 mmol).  The reaction 
was allowed to stir at room temperature for 24 h, at which time it was diluted with EtOAc 
(75 mL) and washed with saturated NaHCO3 (40 mL), and brine (40 mL).  The organic 
layer was dried over Na2SO4, filtered, and concentrated to yield the crude product.  
Purification by column chromatography (010% EtOAc/hexanes) yielded the product as 
O
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an oil (1.28g, 56%). Rf 0.65 (20% EtOAc/hexanes); 1H NMR: (500 MHz, CDCl3) δ 0.84 
(d, J=5.05 Hz, 6H), 1.35 (s, 9H), 1.43 (s, 6H), 1.72 (m, 1H), 2.54 (m, 2H), 3.59 (s, 3H), 
3.66-3.80 (m, 1H), 4.36 (d, J=6.54 Hz, 1H); 13C NMR: (125 MHz, CDCl3) δ 19.0, 21.5, 
23.1, 24.7, 25.9, 26.6, 28.2, 34.2, 51.6, 62.9, 73.0, 79.4, 92.7, 153.1, 170.9; IR (cm -1):  
2971, 2930, 1742, 1697, 1375, 1173; HRMS (ESI) m/z calculated for C16H29NO5Na (M + 
Na)+: 338.1944, found: 338.1953; 
! 
"[ ]D
22.5  +24.34 (c  0.9 CH2Cl2).  
Oxazolidine carboxylic acid (31). Oxazolidine 23 (1.28 g, 
4.10 mmol) was dissolved in 1:1 THF/MeOH (20 mL) and 
cooled to 0 °C.  To this was added 0.1M LiOH (8 mL) 
dropwise.  The reaction was allowed to warm to room temperature and stir overnight.  
The solvent was evaporated and the remaining aqueous solution was acidified with 10% 
KHSO4.  This solution was then extracted with EtOAc (3 x 30 mL) and the combined 
aqueous extracts were dried over Na2SO4, filtered, and concentrated to yield the product 
(1.22 g, quantitative) as an oil which was used without further purification. 
 
Coupled oxazolidine (33). Hiv-Leu-Pro-OBn (8) 
(50 mg, 0.119 mmol) and carboxylic acid 24 (40 
mg, 0.131 mmol) were dissolved in anhydrous 
tetrahydrofuran (1 mL) and cooled to 0 °C.  To this 
solution was added EDCI (27 mg, 0.143 mmol) and 
DMAP (1.4 mg, 0.0119 mmol).  The reaction was 
allowed to warm to room temperature and stir overnight.  The reaction was diluted with 
EtOAc (50 mL) and washed with 10% HCl (20 mL), saturated NaHCO3 (20 mL), and 
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brine (20 mL).  The organic layer was dried over Na2SO4, filtered and concentrated to 
yield the crude product.  Purification by column chromatography (2040% 
EtOAc/hexanes) yielded the product as a white solid (78 mg, 94%). Rf 0.25 (30% 
EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 0.85-0.99 (m, 18H), 1.44 (s, 9H), 1.52 
(m, 6H), 1.40 (m, 1H), 1.86 (s, 2H), 1.99 (m, 3H), 2.13-2.31 (m, 2H), 2.76 (d, J= 5.85 
Hz, 2H), 3.56 (q, J= 7.45 Hz, 1H), 3.70 (m, 1H), 3.87 (s, 1H), 4.41 (m, 1H) 4.51 (dd, 
J=8.52, 4.23 Hz, 1H), 4.88 (q, J= 8.20 Hz, 1H), 5.00-5.19 (m, 3H), 6.66 (d, J= 8.70 Hz, 
1H), 7.31 (m, 5H); 13C NMR (125 MHz, CDCl3) δ 17.0, 18.7, 21.7, 23.3, 24.6, 24.8, 28.3, 
28.9, 30.6, 34.9, 42.1, 46.8, 48.5, 58.8, 63.2, 66.9, 67.8, 72.8, 78.3 79.8, 92.9, 128.1, 
128.4, 128.5, 135.5, 164.9, 168.8, 169.9, 170.6, 171.6; IR (cm -1): 3306, 2966, 2935, 
2876, 1745, 1694, 1648, 1451, 1367, 1173; HRMS (ESI) m/z calculated for C38H60N3O9 
(M + H)+: 702.4251, found: 702.4330; 
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19.6  -42.04 (c  1.00, CH2Cl2). 
 
Protected linear precursor (8). Coupled 
oxazolidine 25 (215 mg, 0.306 mmol) was 
dissolved in 4.0 M HCl in dioxane (5 mL) 
and allowed to stir for 3 h.  The solvent 
was evaporated and to the residue was 
added Et2O and the solution was 
subsequently evaporated and kept under reduced pressure overnight to yield the HCl salt 
as a white solid.   This HCl salt (183 mg, 0.306 mmol) was dissolved in anhydrous 
dichloromethane (3.8 mL) and the solution was cooled to 0 °C. Acid 6 (200 mg, 0.367 
mmol), BOP (169 mg, 0.383 mmol), and DIPEA (187 µL, 1.07 mmol) were added 
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successively to the reaction vessel.  The reaction was allowed to warm to room 
temperature and stir for 24 h.  The mixture was diluted with EtOAc (10 mL) and washed 
with 10% HCl (5 mL), saturated NaHCO3 (5 mL), and brine (5 mL).  The organic layer 
was dried over Na2SO4, filtered, and concentrated to yield the crude product which was 
purified by column chromatography (3040% EtOAc/hexanes) to yield the product as 
an amorphous solid (251 mg, 76%). Rf 0.28 (30% acetone/hexanes); 1H NMR (500 MHz, 
CDCl3) δ 0.74-0.98 (m, 18H), 1.22 (d, J=5.34 Hz, 3H), 1.43 (s, 9H), 1.64 (m, 2H), 1.96 
(m, 5H), 2.17 (m, 3H), 2.54 (m, 1H), 2.70 (m, 1H), 2.80 (m, 3H), 2.94 (m, 1H), 3.19 (dd, 
J=12.9, 5.2 Hz, 1H), 3.58 (m, 1H), 3.63 (s, 1H), 3.73 (s, 3H), 3.80 (m, 1H), 4.04 (t, J= 
6.70 Hz, 1H), 4.10 (m, 1H), 4.35 (s, 1H), 4.45 (m, 1H), 4.77-4.89 (m, 2H), 4.92 (d, 
J=4.81 Hz, 1H), 5.00 (m, 2H), 5.05-5.14 (m, 1H), 5.19 (m, 1H), 5.26 (m, 1H), 5.50 (d, J= 
8.44 Hz, 1H), 6.74 (d, J= 8.00 Hz, 2H), 7.01 (m, 2H), 7.29 (m, 10H), 7.46 (m, 1H); 13C 
NMR (125 MHz, CDCl3) δ 13.6, 16.9, 17.7, 18.3, 18.5, 19.1, 20.2, 20.9, 21.1, 23.3, 24.7, 
28.1, 28.8, 30.4, 31.9, 34.0, 38.7, 40.1, 46.9, 48.4, 55.1, 58.9, 64.3, 66.9, 67.3, 68.6, 70.2, 
78.6, 80.2, 113.9, 127.6, 127.9, 128.1, 128.4, 128.5, 129.7, 129.8, 135.4, 156.1, 156.8, 
158.3, 169.9, 170.0, 171.3, 171.6, 171.9; IR (cm -1):  3329, 2961, 2935, 2875, 1744, 1686, 
1637, 1514, 1454, 1248, 1173; HRMS (ESI) m/z calculated for C58H81N5O15Na (M+Na)+: 
1110.5627, found: 1110.5609; 
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20.2  -44.34 (c  1.00, CH2Cl2). 
 
Tamandarin B macrocycle (2). Protected 
linear precursor 5 (40mg, 0.037 mmol) was 
dissolved in anhydrous methanol (4 mL).  To 
this was added 10% Pd(OH)2/C (4 mg, 10% 
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wt.).  The flask was evacuated, purged with hydrogen, and allowed to stir overnight.  The 
reaction mixture was diluted with dichloromethane (15 mL) and the solution was filtered 
through a pad of Celite, and concentrated to yield the product (32 mg, quantitative) as a 
white solid, which was used without further purification.  This deprotected product (32 
mg, 0.037 mmol) was dissolved in anhydrous DMF (37 mL) and cooled to 0 °C.  To this 
was added PyAOP (33 mg, 0.063 mmol) and NMM (20 µL, 0.19 mmol).  The reaction 
was allowed to warm to room temperature and stir overnight.  After 24 h additional 
PyAOP (19 mg, 0.36 mmol) and NMM (4 µL) were added and the reaction was stirred 
for an additional 24 h.  To the reaction mixture was added water (50 mL).  This solution 
was then extracted with EtOAc (4 x 50 mL).  The combined organic phases were washed 
with 10% KHSO4 (30 mL), 5% NaHCO3 (30 mL), and brine (30 mL).  The organic layer 
was dried over Na2SO4, filtered and evaporated to yield the crude product, which was 
purified by column chromatography (40% EtOAc/CH2Cl2) to yield the product (14 mg, 
48%) as a white solid. Rf  0.2 (50% EtOAc/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 0.80-
1.03 (m, 18H), 1.25 (d, J= 6.45 Hz, 3H), 1.43 (s, 9H), 1.53-1.71 (m, 4H), 1.73-1.80 (m, 
4H), 1.96-2.21 (m, 4H), 2.46 (dd, J=16.96, 6.72 Hz), 2.56 (s, 3H), 2.85-2.94 (m, 1H), 
3.14 (dd, J= 14.44, 10.89 Hz,1H), 3.36 (dd, J= 14.22, 4.32 Hz, 1H), 3.55 (dd, J= 10.47, 
4.47 Hz, 1H), 3.64 (d, J= 6.00 Hz, 2H), 3.70 (t, J= 9.29 Hz, 1H), 3.77 (s, 3H), 3.98 (t, J= 
6.16 Hz, 1H), 4.32 (dd, J= 10.37, 3.12 Hz, 1H), 4.58 (dd, J= 7.85, 4.60 Hz, 1H), 4.88 (t, 
J= 9.92 Hz, 1H), 4.95 (m, 2H), 5.00 (dd, J= 6.30, 3.20 Hz, 1H), 6.82 (d, J= 8.44 Hz, 2H), 
7.06 (d, J= 8.44 Hz, 2H), 7.53 (d, J= 9.64 Hz, 1H), 7.95 (d, J= 8.49 Hz, 1H); 13C NMR 
(125 MHz, CDCl3) δ 15.1, 18.0, 18.5, 20.2, 20.7, 23.5, 24.9, 27.6, 28.0, 30.4, 34.0, 38.5, 
38.9, 46.7, 48.3, 55.2, 55.8, 57.1, 60.3, 65.8, 68.9, 71.4, 79.2, 80.2, 114.1, 129.9, 130.3, 
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155.8, 158.6, 168.6, 169.7, 170.4, 171.3, 171.6, 172.8; IR (cm -1):  3341, 2961, 2873, 
1741, 1669, 1636, 1514, 1166; HRMS (ESI) m/z calculated for C43H68N5O12 (M +H)+: 
846.4864, found: 846.4869; 
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18.7
  -90.1 (c   0.7, CH2Cl2). 
Boc-D-Leucine benzyl ester.  D-Leucine (5 g, 38.1 mmol) was 
suspended in 1 M NaOH (76 mL) and dioxane (23 mL) and 
cooled to 0 °C.  To this solution was added Boc anhydride (9.15 
g, 41.9 mmol) in dioxane (30 mL).  The reaction was allowed to 
warm to room temperature and stir overnight.  The reaction mixture was diluted with 
water (100 mL) and extracted with hexanes (3 x 100 mL).  The remaining aqueous layer 
was acidified with solid citric acid and extracted with ethyl acetate (3 x 100 mL).  The 
organic extracts were washed with water (50 mL), brine (50 mL) and dried over MgSO4.  
Filtration and concentration under reduced pressure led to the product as clear oil (8.51 g, 
97%) that was used directly in the next step.  The Boc protected product (8.51 g, 36.8 
mmol) was dissolved in anhydrous DMF (75 mL) and cooled to 0 °C.  To this solution 
was added cesium carbonate (12.0 g, 36.8 mmol) and the reaction was allowed to stir for 
20 min.  Benzyl bromide (4.37 mL, 36.8 mmol) was added to the reaction mixture via 
syringe.  This mixture was allowed to warm to room temperature and stir overnight.  
Water (300 mL) was added to the reaction and was then extracted with hexanes (3 x 150 
mL).  The combined organic extracts were washed with water, brine, and dried over 
MgSO4. Concentration under reduced pressure led to the product as a clear oil (10.76 g, 
91%):  Rf   0.41 (10% EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 0.92 (d, J= 4.10 
Hz, 3H), 0.93 (d, J= 4.10 Hz), 1.46 (s, 9H), 1.49 (m, 1H), 1.65 (m, 2H), 4.49 (s, 1H), 4.89 
(s, 1H), 5.16 (q, J= 13.4 Hz, 2H), 7.32 (m, 5H); 13C NMR (125 MHz, CDCl3) δ 21.9, 
O
OBn
NHBoc
 78 
22.8, 24.8, 28.3, 41.7, 52.1, 66.9, 79.8, 128.1, 128.3, 128.5, 135.7, 155.5, 173.5;  IR 
(neat, cm-1): 3365, 2958, 1718, 1508, 1366, 1251, 1164;  HRMS (ESI)  m/z calculated for 
C18H27NO4Na (M+Na)+:  344.1838, found: 344.1850;  
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22.8  32.56 (c 1.12, MeOH).  
N-Me-N-Boc-D-Leucine benzyl ester (52). N-Boc-Leucine 
benzyl ester (3.61 g, 11.2 mmol) was dissolved in anhydrous THF 
(56 mL) and cooled to 0 °C.  Methyl iodide (3.54 mL, 56.2 mmol) 
was added to this solution followed by 1M NaHMDS (16.8 mL, 16.8 mmol).  The 
reaction mixture was allowed to warm to room temperature and stir overnight.  The 
reaction was quenched by addition of saturated ammonium chloride (50 mL). The 
reaction mixture was extracted with diethyl ether (2 x 50 mL).  The combined organic 
phases were washed with 10 % HCl (30 mL), saturated NaHCO3 (30 mL), brine (30 mL), 
and dried over MgSO4.  The solvent was evaporated to yield the crude product as a 
brown oil.  The oil was purified by column chromatography (24% EtOAc/hexanes) to 
yield the product as a clear oil (2.76g, 73%): Rf 0.40 (10% EtOAc/hexanes); 1H NMR 
(500 MHz, CDCl3) δ 0.92 (d, J= 6.55 Hz, 3H), 0.94 (d, J= 5.83 Hz, 3H), 1.43 (s, 9H), 
1.56 (m, 1H), 1.68 (m, 2H), 2.79 (m, 3H), 4.6-4.8 (m, 1H), 5.15 (m, 2H), 7.33 (m, 5H);  
13C NMR (125 MHz, CDCl3) δ 21.2, 23.7, 24.6, 28.2, 32.4, 37.4, 56.0, 57.2, 66.5, 80.1, 
127.3, 128.2, 128.5, 135.7, 155.4, 156.2, 172.26;  IR (neat, cm-1) 2958, 1740, 1702, 1455, 
1391, 1367, 1323, 1156, 970;  HRMS (ESI) m/z  calculated for C19H29NO4Na (M + Na)+: 
358.1995, found: 358.1990;  8.24][ D!   23.96 (c 1.0, MeOH). 
N-Me-D-Leucine benzyl ester hydrochloride. N-Me-N-Boc-D-
Leucine benzyl ester (6.47 g, 19.29 mmol) was dissolved in 4.0 M 
O
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HCl in dioxane (20 mL) at room temperature.  The reaction was complete after 2 h.  The 
solvent was evaporated to yield the product (5.24 g, quantitative) as a white solid, which 
was used without further purification. 
N-Boc-Proline-N-Me-D-leucine benzyl ester (53). Boc-
Proline (2.99 g, 13.9 mmol) was dissolved in anhydrous 
CH2Cl2 (46 mL) and cooled to -15 °C.  To this solution was 
added BOP-Cl (3.72 g, 14.6 mmol) and NMM (1. 64 mL, 14.8 mmol).  This mixture was 
stirred for 30 minutes, then N-methyl-D-leucine-benzyl ester hydrochloride (3.78 g, 13.9 
mmol) and NMM (5 mL, 45.9 mmol) were added.  The reaction was allowed to warm to 
room temperature and stirred for 24 h.  The mixture was diluted with EtOAc (100 mL), 
washed with 10% HCl (30 mL), saturated NaHCO3 (30 mL), brine (30 mL), dried over 
MgSO4, and filtered.  After solvent evaporation the crude product was purified by 
column chromatography (1020% acetone/hexanes) to yield the product (4.75 g, 92%) 
as a white solid:  Rf  0.5  (30% acetone/hexanes);  1H NMR (500 MHz, CDCl3) δ 0.91 (m, 
6H) 1.40 (m, 9H), 1.63 (s, 1H) 1.70-1.78 (m, 1H), 1.79-2.20 (m, 3H), 3.02 (m, 3H) 3.37-
3.48 (m, 1H), 3.53-3.69 (m, 1H), 4.60 (dd, J=8.59, 3.39 Hz), 5.14 (m, 2H), 7.32 (m, 5H);  
13C NMR (125MHz, CDCl3) δ  21.2, 23.3, 25.1, 28.2, 30.4, 31.7, 32.6, 37.8, 46.4, 55.2, 
57.1, 66.7, 79.5, 128.1, 128.5, 135.6, 153.9, 171.6, 173.3;  IR (neat, cm-1): 2958, 2931, 
2872, 1741, 1699, 1661, 1396, 1169;  HRMS (ESI) m/z calculated for C24H36N2O5Na (M 
+ Na)+: 455.2522, found: 455.2515; 
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25.8  -1.54 (c 1.0, CH2Cl2). 
L-Lactyl-L-prolyl-N-methyl-D-leucine benzyl ester 
(41). Benzyl ester 30 (300 mg, 0.69 mmol) was dissolved 
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in 4.0 M HCl in dioxane (3 mL) and allowed to stir at room temperature for 2 h. The 
solvent was removed and the resulting salt was redissolved in anhydrous CH2Cl2 (3 mL) 
and cooled to 0 °C.  To this solution was added L-lactic acid (52 µL, .69 mmol), BOP 
(.368 g, .83 mmol), and NMM (.31 mL, 2.78 mmol).  The mixture was allowed to warm 
to room temperature and stir overnight.  The reaction was diluted with CH2Cl2 (25 mL) 
and washed with 10% HCl (10 mL), saturated NaHCO3 (10 mL), and brine (10 mL).  The 
organic phase was dried over Na2SO4, filtered, and concentrated.  The crude product was 
purified by column chromatography (25% acetone/hexanes) to yield the product (0.172 g, 
61%) as a clear oil:  Rf  0.48 (50% acetone/hexanes);  1H NMR (500 MHz, CDCl3) δ 
0.78-1.01 (m, 6H), 1.33 (m, 6H), 1.43 (m, 2H), 1.74 (m, 2H), 1.91 (m, 2H), 2.09 (m, 2H), 
3.01 (s, 3H), 3.52 (t, J=6.75 Hz, 2H), 4.29 (q, J=5.98 Hz, 1H), 5.15 (m, 3H), 7.31 (m, 
5H);  13C NMR (125 MHz, CDCl3) δ 20.4, 21.3, 23.1, 24.8, 28.3, 32.1, 37.4, 46.5, 55.6, 
568, 65.5, 66.6, 128.0, 128.4, 128.6, 135.6, 171.1, 172.1, 173.2;  IR (neat, cm-1): 3415, 
2957, 2873, 1739, 1651, 1456, 1129, 843; HRMS (ESI) m/z calculated for C22H32N2O5Na 
(M + Na)+: 427.2209, found: 427.2194;  
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25.6 -14.07 (c 0.76, CHCl3). 
Pyruvyl-prolyl-N-methyl-D-leucine benzyl ester. Lactyl-
prolyl-N-methyl-D-leucine benzyl ester (120 mg, 0.296 
mmol) was dissolved in anhydrous CH2Cl2 (1.00 mL) and 
dimethyl sulfoxide (0.30 mL).  To this solution was added Dess-Martin periodinane (629 
mg, 1.48 mmol).  The reaction was allowed to stir for 24 h at which time it was quenched 
with 5% Na2S2O3 (5 mL) and diluted with Et2O (25 mL).  The organic layer was 
separated and washed with saturated sodium bicarbonate (5 mL), water (5 mL), dried 
over Na2SO4, filtered and concentrated.  The crude product was purified by column 
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chromatography (20% acetone/hexanes) to yield the product (87 mg, 73%) as a yellow 
oil:  Rf  0.27 (30% acetone/hexanes); 1H NMR (CDCl3, 500 MHz) δ 0.91 (m, 6H), 1.43 
(m, 1H), 1.60-1.90 (m, 6H), 2.20-2.45 (m, 3H), 2.81-3.10 (m, 3H), 3.52-3.92 (m, 2H), 
4.92 (m, 1H), 5.04-5.22 (m, 3H), 7.36 (m, 3H); 13C NMR (CDCl3, 125 MHz) δ 21.2, 22.3, 
23.3, 24.9, 26.1, 31.1, 32.1 37.2, 47.5, 57.8, 58.5, 66.9, 128.1, 128.3, 128.5, 136.5, 163.6, 
170.9 172.6, 198.7;  IR (neat, cm-1):  3460, 2958, 2873, 1739, 1715, 1652, 1455, 1206;  
HRMS (ESI) m/z calculated for C22H30N2O5Na (M + Na)+:  425.2052, found: 425.2040;  
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20.5  -2.58 (c 0.96, CHCl3). 
Procedure for preparation of tamandarin B macrocyclic salt.  Macrocycle  (14 mg, 
0.017 mmol) was dissolved in EtOAc (4 mL) and cooled to -30 ºC. HCl gas was bubbled 
over this solution while keeping the temperature at -30 ºC for 10 min.  The flow of HCl 
gas was stopped and stirring continued at -30 ºC for an additional 30 min.  The 
temperature was raised to 0 ºC for 1 h.  At this point TLC showed that the starting 
material had been consumed.  The solvent was removed under reduced pressure to yield 
the macrocyclic salt (13 mg, quantitative) as a yellow solid, which was used without 
further purification.  
Dehydrotamandarin B (35).  The 
tamandarin B macrocyclic salt (8.0 
mg, 0.010 mmol) was dissolved in 
anhydrous CH2Cl2 (1 mL) and 
cooled to 0 °C.  To this solution 
was added side chain 40 (5.0 mg, 
0.015 mmol), BOP (7.0 mg, 0.15 mmol) and NMM (4.5 µL, 0.041 mmol).  The reaction 
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was allowed to warm to room temperature and stir overnight.  The reaction was quenched 
with brine (4 mL) and the mixture was extracted with EtOAc (3 x 10 mL).  The organic 
phase was washed with 10% HCl (5 mL), 5% NaHCO3 aq. (5 mL), brine (5 mL), dried 
over Na2SO4, filtered and concentrated to yield the crude product.  The product was 
purified by reverse phase HPLC (10% MeOH/H2O100% MeOH gradient over 40 
minutes) to yield the product (8 mg, 73%) as a white solid. Rf 0.26 (30% 
acetone/hexanes); 1H NMR (500 MHz, CDCl3) δ 0.78-1.07 (m, 24H), 1.25 (m, 10H) 1.40 
(t, J= 7.49 Hz, 3H), 1.45 (m, 1H), 1.61 (m, 5H), 1.72-2.28 (m, 10H), 2.43-2.50 (m, 1H), 
2.53-2.62 (m, 3H), 3.03-3.12 (m, 3H), 3.13-3.20 (m, 1H), 3.55-3.74 (m, 3H), 3.79 (s, 
3H), 3.81-3.89 (m, 1H), 3.91-4.04 (m,1H), 4.28-4.40 (m, 1H), 4.63 (m, 1H), 4.89 (t, J= 
10.17 Hz, 1H), 5.05 (d, J=4.49 Hz, 1H), 5.16-5.27 (m, 1H), 5.28-5.36 (m, 1H), 6.84 (m, 
2H), 7.08 (d, J= 7.91 Hz, 2H), 7.42-7.56 (m, 1H), 7.72-7.85 (m, 1H); 13C NMR (125 
MHz, CDCl3) δ  14.1, 16.6, 17.0, 17.4, 18.9, 20.4, 20.8, 21.4, 22.7, 23.5, 23.8, 24.9, 26.3, 
27.1, 28.0, 29.4, 29.7, 30.0, 30.6, 31.2, 34.0, 35.8, 38.7, 39.2, 46.7, 48.7, 48.8, 54.7, 55.2, 
56.9, 57.3, 58.3, 58.9, 66.0, 70.9, 78.7, 114.1, 129.8, 130.3, 158.6, 161.3, 168.6, 169.6, 
170.4, 170.5, 171.7, 172.2, 172.9, 173.9, 201.11. IR (cm-1) 3340, 2957, 2926, 2871, 1741, 
1662, 1636, 1514, 1457, 1170, 1078; HRMS (ESI) m/z calcd for C53H81N7O14Na (M + 
Na)+: 1062.5739, found: 1062.5760; 
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17 -18.68 (c 0.2, CH2Cl2). 
N2-Boc-N5-Xanthyl-glutaminyl-O-L-lactyl-L-
prolyl-N-methyl-D-leucine benzyl ester (42).  L-
Lactyl-L-prolyl-N-methyl-D-leucine benzyl ester 
(2.24 g, 5.5 mmol) was dissolved in anhydrous 
O
BnO
N
Me
O
N
O
O
O
NHBoc
O NHXan
 83 
THF (30 mL) and cooled to 0 °C.  To this solution was added N2-Boc-N5-glutamine (3.07 
g, 7.2 mmol), followed by EDCI (1.48 g, 7.7 mmol) and DMAP (1.34 g, 11 mmol).  The 
reaction was allowed to warm to room temperature and stir overnight.  EtOAc (50 mL) 
was added and the solution was washed sequentially with 10% HCl (25 mL), saturated 
NaHCO3 (25 mL), brine (25 mL), dried over MgSO4, filtered, and concentrated.  The 
crude product was purified by column chromatography (1520% acetone/hexanes) to 
yield the product (3.70 g, 83%) as a white solid:  Rf 0.54 (50% acetone/hexanes);  1H 
NMR (500 MHz, CDCl3) δ 0.73 (t, J= 6.63 Hz, 2H), 0.80 (d, J=6.50 Hz, 2H), 0.86 (d, J= 
6.65 Hz, 3H), 0.97 (dd, J= 16.2, 6.53 Hz, 1H), 1.35 (d, J=5.85 Hz, 3H), 1.43 (s, 9H), 
1.60-1.69 (m, 2H), 1.78-1.88 (m, 2H), 1.88-2.20 (m, 3H), 2.22-2.42 (m, 2H), 2.70 (m, 
3H), 2.89-2.98 (m, 1H), 3.43-3.69 (m, 2H), 3.72 (t, J=6.25 Hz, 2H), 4.31-4.64 (m, 1H), 
4.91 (m, 2H), 5.11 (m, 2H), 6.50 (m, 1H), 7.00-7.12 (m, 4H), 7.18-7.37 (m, 7H), 7.39-
7.51 (m, 2H);  13C NMR (125 MHz, CDCl3) δ 11.4, 14.1, 16.0, 21.3, 22.5, 23.1, 24.9, 
25.3, 28.3, 29.0, 31.5, 32.0, 34.6, 36.0, 37.3, 43.5, 46.7, 55.8, 56.7, 66.3, 116.2, 121.2, 
123.3, 123.5, 127.9, 128.4, 128.8, 129.4, 135.7, 151.1, 168.6, 170.1, 171.9, 172.1;  IR 
(neat, cm-1): 3305, 2959, 1743, 1712, 1652, 1481, 1456, 1258;  HRMS (ESI) m/z 
calculated for C45H56N4O10Na (M + Na+): 835.3894, found: 835.3992;  
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24.0   -27.24 (c 
0.89, CHCl3). 
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Protected Tamandarin M side chain. N2 Boc-
N5-Xanthyl-glutaminyl-O-L-lactyl-L-prolyl-N-
methyl-D-leucine benzyl ester (407 mg, 0.50 
mmol) was dissolved in EtOAc (4.75 mL) and 
anisole (0.25 mL) and cooled to -20 °C.  
Gaseous HCl was added over a 5 minute period in which the reaction went from yellow 
to red.  The reaction was allowed to stir at -20 °C for 1 h and at 0 °C for 1 h.  Argon was 
then bubbled through the solution as it was allowed to warm to room temperature.  The 
solvent was evaporated and the remaining residue was triturated with diethyl ether (10 
mL) to produce a white solid, which was removed by filtration.  The remaining ether 
solution was evaporated and triturated again to produce a second crop of the 
hydrochloride salt.  The product was isolated as a white solid (0.182g, 64%) that was 
used in the next step without further purification.  The HCl salt (0.182g, 32 mmol) was 
dissolved in anhydrous dichloromethane (1.4 mL) and cooled to 0 °C.  To this solution 
was added N-Cbz-pGlu-OPfP (0.140 g, 32 mmol) and DIPEA (225 µL, 1.28 mmol). The 
mixture was allowed to warm to room temperature and stir overnight.  The reaction was 
quenched with brine (3 mL) and diluted with CH2Cl2 (5 mL).  The layers were separated 
and the aqueous layer was extracted with CH2Cl2 (3 x 5 mL).  The combined organic 
extracts were washed with 10 % HCl (5 mL), 5% NaHCO3 aq. (5 mL), and brine (5 mL).  
The organic layer was dried (MgSO4), filtered and evaporated to yield the crude product 
which was purified by column chromatography (1-5% MeOH/CH2Cl2) to yield the 
product (77 mg, 31%) as a white solid:  Rf  .41 (10% MeOH/CH2Cl2); 1H NMR (CDCl3, 
O
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N
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500 MHz) δ 0.86 (d, J=6.52 Hz, 3H), 0.91 (d, J=6.67 Hz, 3H), 1.38 (m, 1H), 1.44-1.57 
(m, 3H), 1.69-1.79 (m, 3H), 1.93-2.33 (m, 9H), 2.35-2.47 (m, 2H), 2.68 (t, J= 9.87 Hz, 
1H), 2.71 (t, J= 9.97 Hz, 1H), 2.99 (s, 3H), 3.57 (q, J= 7.68 Hz, 1H), 3.70 (q, J= 7.75 Hz, 
1H), 4.46-4.60 (m, 2H), 4.86 (dd, J=8.40, 4.76 Hz, 1H, 5.05-5.28 (m, 4H), 5.42 (m, 1H), 
6.93 (s, 1H), 7.24-7.39 (m, 10H), 7.51 (d, J= 6.55 Hz, 1H);  13C NMR (CDCl3, 125 MHz) 
δ 15.8, 21.1, 22.2, 23.2, 24.9, 25.1, 27.1, 28.3, 31.1, 31.3, 31.6, 37.4, 46.7, 51.9, 55.0, 
57.2, 59.5, 66.8, 68.2, 69.2, 127.9, 128.2, 128.5, 128.6, 135.1, 135.5, 151.3, 168.6, 170.7, 
171.1, 171.5, 171.9, 173.5, 175.6;  IR (neat, cm-1): 3432, 3328, 3214, 2951, 1791, 1742, 
1661, 1452, 1304, 1189;  HRMS (ESI) m/z calculated for C40H51N5O11Na (M + Na)+: 
800.3483, found: 800.3495; 
! 
"[ ]D
27 -57.03 (c 0.77, CHCl3). 
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 Tamandarin M (34).  The tamandarin B macrocyclic salt (10.0 mg, 0.013 mmol) was 
dissolved in anhydrous CH2Cl2 (1 mL) and cooled to 0 °C.  To this solution was added 
side chain 35 (11.0 mg, 0.019 mmol), BOP (9.0 mg, 0.019 mmol), and NMM (6.0 µL, 
0.051 mmol).  The reaction was allowed to warm to room temperature and stir overnight.  
The reaction was quenched with brine (4 mL) and the resulting mixture was extracted 
with EtOAc (3 x 10 mL).  The organic phase was washed with 10 % HCl (5 mL), 5% 
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NaHCO3 aq. (5 mL), brine (5 mL), dried over Na2SO4, filtered, and concentrated to yield 
the crude product.  The product was purified by reverse phase HPLC (10% 
MeOH/H2O100% MeOH gradient over 40 minutes) to yield the product (13 mg, 81%) 
as a white solid.  Rf 0.21 (50% EtOAc/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ  0.76-1.05 
(m, 24H), 1.15-1.32 (m, 10H), 1.36-1.42 (m, 5H), 1.46 (d, J= 7.07 Hz, 2H), 1.52-1.66 (m, 
3H), 1.72 (m, 2H), 1.89 (m, 2H), 1.96-2.31 (m, 9H), 2.34-2.46 (m, 2H), 2.54 (s, 3H), 2.61 
(m, 1H), 2.92 (m, 1H), 2.97 (s, 2H), 3.06-3.16 (m, 2H), 3.32 (dd, J= 14.16, 3.95 Hz, 1H), 
3.53-3.74 (m, 4H), 3.77 (s, 3H), 3.87 (m, 2H), 4.15 (t, J= 4.16 Hz, 1H), 4.49 (m, 2H), 
4.57 (dd, J= 7.73, 4.68 Hz, 1H), 4.74 (t, J= 7.05 Hz, 1H), 4.87 (m, 1H), 4.91 (d, J= 5.05 
Hz, 1H), 5.01 (m, 1H), 5.11 (q, J= 6.70 Hz, 1H), 5.25 (dd, J= 9.45, 6.00 Hz, 1H), 5.94 (s, 
1H), 6.81 (d, J= 8.30 Hz, 2H), 7.05 (d, J= 8.35 Hz, 2H), 7.75 (d, J= 9.40 Hz, 1H), 7.80 
(d, J= 9.80 Hz, 1H), 8.52 (d, J= 6.35 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 14.2, 15.9, 
16.1, 16.9, 17.9, 18.8, 20.3, 20.9, 21.4, 22.7, 23.6, 23.7, 24.6, 24.9, 25.7, 27.2, 27.9, 28.8, 
29.3, 29.7, 30.2, 31.1, 31.8, 31.9, 34.0, 26.1, 38.6, 39.2, 39.5, 46.8, 47.1, 48.3, 51.8, 53.8, 
54.3, 55.3, 56.3, 56.6, 56.8, 57.0, 58.4, 66.1, 68.7, 69.5, 71.2, 79.4, 114.1, 129.8, 130.4, 
158.6, 168.8, 169.4, 169.5, 170.5, 170.8, 171.1, 171.3, 172.6, 173.3, 173.5, 176.5, 178.8; 
IR (cm-1) 3337, 2958, 1928, 2873, 1741, 1662, 1636, 1514, 1456, 1248; HRMS (ESI) m/z 
calcd for C63H96N10O18Na (M + Na)=: 1303.6802, found: 1303.6832; 
! 
"[ ]D
17 -35.49 (c 0.65 
CH2Cl2). 
 N-Boc-Prolinal (44).  This compound was prepared according to a 
procedure by Reed.28 The product matched the reported spectral and 
physical characteristics. 
 
N
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O
H
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N-Boc-Pro Ψ(NHCH2) N-Methyl leucine-benzyl ester 
(46). Boc-Prolinal (430 mg, 2.15 mmol) and N-methyl 
leucine benzyl ester (508 mg, 2.15 mmol) were dissolved in 
anhydrous 1,2-dichloroethane (5 mL).  The reaction was 
cooled to 0 °C and acetic acid (0.5 mL) was added and the solution stirred for 20 minutes.  
Sodium triacetoxyborohydride (637 mg, 3.01 mmol) was added to the reaction and the 
mixture was allowed to warm to room temperature and to stir for 3 h.  The reaction was 
quenched with saturated NH4Cl and diluted with CH2Cl2 (15 mL).  The organic layer was 
washed with 10% HCl (10 mL), 5% NaHCO3 aq. (10 mL), brine (10 mL), dried over 
Na2SO4, filtered, and concentrated to yield the crude product.  The crude product was 
purified by column chromatography (1020% EtOAc/hexanes) to afford the product 
(580 mg, 65%) as a yellow oil: Rf  0.68 (30% EtOAc/hexanes); 1H NMR (500 MHz, 
CDCl3) δ 0.89 (m, 6H), 1.42 (s, 9H), 1.56 (m, 1H), 1.68 (m, 1H), 1.80 (m, 4H), 2.30 (m, 
4H), 2.51-2.80 (m, 1H), 3.31 (m, 3H), 3.70-3.95 (m, 1H), 5.13 (m, 2H), 7.35 (m, 5H);13C 
NMR (125 MHz, CDCl3) δ 22.4, 22.9, 24.7, 28.5, 36.8, 39.2, 40.3, 46.1, 55.9, 66.1, 79.1, 
128.2, 128.3, 128.5, 136.0, 154.4, 172.8;  IR (neat, cm-1): 2958, 2873, 1731, 1694, 1456, 
1394, 1171; HRMS (ESI) m/z Calculated for C24H38N2O4Na (M + Na)+: 441.2730, found: 
441.2741;  
! 
"[ ]D
22 +10.7 (c = 0.8 CHCl3).  
L-Lactyl-ProΨ(NHCH2) N-Methyl-D-Leucine benzyl 
ester (47).  N-Boc-Pro Ψ(NHCH2) N-methyl leucine-
benzyl ester (46) (0.128 g, 0.316 mmol) was dissolved in 
4.0 M HCl in dioxane (5 mL).  The reaction was stirred 
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for 2 h and the solvent was evaporated to yield the hydrochloride salt in quantitative 
yield.  The resulting salt (0.122 g, 0.316 mmol) was dissolved in anhydrous CH2Cl2 (2 
mL) and cooled to 0 °C.  To this solution was added L-lactic acid (25 µL, .332 mmol), 
BOP (0.154 g, 0.348 mmol), and NMM (173 µL, 1.58 mmol).  The reaction was allowed 
to warm to room temperature and stir overnight.  The reaction was diluted with EtOAc 
(20 mL) and washed with 10% HCl (10 mL), 5% NaHCO3 aq. (10 mL), and brine (10 
mL).  The organic layer was dried over Na2SO4, filtered, and concentrated to yield the 
crude product.  The crude product was purified by column chromatography (2050% 
EtOAc/hexanes) to yield the product (75 mg, 61%) as a yellow oil:  Rf  0.30 (50% 
EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 0.83-0.92 (m, 6H), 1.29 (d, J= 6.55 Hz, 
3H), 1.38-1.70 (m, 4H), 1.76-2.01 (m, 4H), 2.28-2.48 (m, 5H), 2.64-2.87 (m, 1H), 3.24-
3.50 (m, 3H), 4.06-4.40 (m, 1H), 5.12 (d, J= 4.75 Hz, 2H), 7.33 (m, 5H);  13C NMR (125 
MHz, CDCl3) δ 20.3, 20.9, 22.3, 22.7, 23.4, 23.9, 24.8, 27.7, 29.6, 37.4, 38.4, 46.0, 56.6, 
65.4, 66.0, 128.1, 128.3, 128.4, 135.8, 172.5, 173.6;  IR (neat, cm-1): 3426, 2957, 2925, 
2863, 1731, 1639, 1452, 1127;  HRMS (ESI) m/z calculated for C22H35N2O4 (M + H)+: 
391.2597, found: 391.2585;  
! 
"[ ]D
19  -1.55 (c 0.58, CHCl3). 
Ψ[CH2NH] Amide Surrogate 
(36).  The tamandarin B 
macrocyclic salt (15.0 mg, 0.019 
mmol) was dissolved in 
anhydrous CH2Cl2 (1 mL) and 
cooled to 0 °C.  To this solution 
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was added side chain 48 (12 mg, 0.038 mmol), HATU (12 mg, 0.031 mmol), and DIPEA 
(14 µL, 0.077 mmol).  The reaction was allowed to warm to room temperature and stir 
overnight.  The reaction was diluted with EtOAc (15 mL) and washed with 10% HCl (5 
mL), 5% NaHCO3 aq. (5 mL), brine (5 mL), dried over Na2SO4, filtered and concentrated 
to yield the product (15 mg, 83 %) as a white solid. Rf  0.46 (10 % MeOH/CH2Cl2); 1H 
NMR (500 MHz, CDCl3) δ 0.0-1.05 (m, 24H), 1.19 (m, 1H), 1.25 (t, J= 7.09 Hz, 3H), 
1.29-1.39 (m, 5H), 1.40-1.52 (m, 3H), 1.57-1.81 (m, 5H), 1.82-2.05 (m, 3H), 2.07-2.18 
(m, 3H), 2.33 (d, J= 10.00 Hz, 3H), 2.41 (m, 1H), 2.53 (s, 2H), 2.77 (s, 3H), 2.89 (m, 
1H), 3.12 (m, 2H), 3.28-3.50 (m, 3H), 3.52-3.71 (m, 3H), 3.76 (s, 3H), 3.94 (m, 1H), 4.26 
(m, 2H), 4.56 (m, 2H), 4.84 (d, J= 6.05 Hz, 2H), 5.01 (m, 1H), 6.80 (d, J= 8.15 Hz, 2H), 
7.05 (d, J= 7.95 Hz, 2H), 7.62 (d, J= 9.15 Hz, 1H) 7.68 (d, J= 8.34 Hz, 1H), 7.77 (d, J= 
8.53 Hz, 1H), 8.00 (t, J= 8.90 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 15.5, 16.5, 18.1, 
18.5, 20.3, 20.8, 21.1, 22.0, 22.6, 23.0, 23.5, 24.4, 24.9, 25.1 25.6, 27.6, 28.0, 30.3, 34.1, 
36.0, 36.7, 38.6, 45.8, 46.4, 46.8, 48.3, 54.5, 56.4, 57.1, 57.2, 58.9, 63.6, 64.6, 65.1, 65.4, 
65.8, 68.8, 69.3, 71.3, 79.3, 114.0, 129.8, 130.4, 158.6, 165.8, 168.8, 169.8, 170.3, 171.2, 
172.5, 172.9, 173.2; IR (cm-1) 3339, 2956, 2920, 2868, 1742, 1661, 1654, 1633, 1511, 
1094; HRMS (ESI) m/z calcd for C53H86N7O13 (M + H)+: 1028.6284, found: 1028.6300; 
! 
"[ ]D
18 -65.55 (c 0.34, CH2Cl2). 
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Chapter 3 
 
3.1) The Total Synthesis of Lys3 Tamandarin M 
 
With the impressive biological activity shown by tamandarin M (34, Chapter 2) attention 
was turned to determining the mechanism of action of the tamandarins and didemnins 
related to their immunosuppressive and antitumor activity.  It was originally thought that 
these compounds’ ability to inhibit protein biosynthesis was the source of these two 
characteristics but this was proven not to be the case.1 As discussed in Chapter 1 (pg. 34) 
Crews and Schreiber conducted two studies, with moderately active didemnin A analogs, 
and isolated two didemnin binding proteins (EF-1α and PPT1).2,3 It is known that the 
biological activity of this class of molecules is highly dependent on the structure of the 
side chains, so an analog with a fully elaborated side chain would be advantageous.  With 
that in mind, Lys3 didemnin B (2) was synthesized in a similar manner to didemnin B 
(Scheme 3.1).4,5 In this molecule the leucine residue was replaced with a lysine residue.  
The advantage of this analog was that the exocyclic nitrogen of the lysine residue could 
be used as an attachment for a biological probe far removed from the side chain.  
Unfortunately this compound was never used in a protein affinity study. 
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Scheme 3.1:  The synthesis of Lys3 didemnin B. 
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With renewed interest in these compounds a similar study was started, with two main 
differences.  The first difference was  that instead of using a Lys3 didemnin macrocycle, a 
Lys3 tamandarin B macrocycle was chosen because it was thought to maintain the same 
biological activity and to be more synthetically accessible.   The second difference was 
that instead of using the didemnin B side chain, the didemnin M side chain was chosen 
due to the impressive activity shown by tamandarin M (Chapter 2, pg. 62, 65).  With 
these modifications in mind, the synthetic target for these studies was Lys3 tamandarin M 
(3) shown in Figure 3.1. 
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Figure 3.1: Structure of Lys3 tamandarin M. 
 
The original retrosynthesis of this molecule is shown in Scheme 3.2. The side chain was 
removed from the macrocycle to yield the Boc protected macrocycle (4) and the side 
chain acid (not shown).  The macrocycle was then opened at the Hiv2-Lys3 junction to 
form 5. This linear precursor was divided into two fragments, a tetrapeptide fragment (6) 
and the Hiv-norstatine allyl ester (7) (Scheme 3.2).6 This retrosynthesis is analogous to 
the didemnin B retrosynthesis used by Joullié.7   
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Scheme 3.2:  Original retrosynthesis of Lys3 tamandarin M. 
Tetrapeptide 6 was synthesized first.  The first step was protection of the α-amino group 
of N-ε-Cbz-Lys (8) as its Troc carbamate (9).  The resulting protected product was 
coupled to Pro-OMe•HCl, and subsequent hydrolysis of the methyl ester afforded acid 
10. Acid 10 was then coupled to amine 11 (69, synthesis described in Chapter 1, pg. 27)7 
to form the fully elaborated, protected tetrapeptide.  Treatment of this product with 
MgBr2•Et2O removed the SEM group to provide the free acid (6). 
 
 
 162 
O
OHCbzHN
NH2
1) Troc-Cl, Na2CO3, dioxane, H2O, 87%
2) Pro-OMe•HCl, PyBroP, iPr2NEt, 
    CH2Cl2, 77%
O
OH
CbzHN
NHTroc
1) Pro-OMe•HCl, PyBroP, 
    iPr2NEt, CH2Cl2, 77%
2) LiOH, THF, H2O, 74%
N
O
NHTroc
CbzHN
OH
O
1)BOPCl, NMM, CH2Cl2, 67%
OMe
NH
O
O
NHBoc
OSEMO
8                                                                                             9
10                               11                                                                                                 6
O
NHBoc
OO
N
OMe
O
N
O
HO
NHTroc
CbzHN
+ 2) MgBr2•Et2O, CH2Cl2, 97%
 
Scheme 3.3:  Synthesis of tetrapeptide 6. 
 
Fragment 7 was prepared next.  This compound was made from a previously synthesized 
acid (10, Chapter 2, pg. 45).  This acid (12) was subjected to esterification with hydroxy 
ester 13 using EDCI and catalytic DMAP to afford 7 (Scheme 3.4). 
NHBoc
OH
OTBSO
12                                                                                                            7
EDCI, DMAP, CH2Cl2, 53%
O
O
OH
NHBoc
O
OTBSO
O
O
13  
Scheme 3.4:  Synthesis of allyl ester 7. 
 
With the desired fragments in hand, allyl ester 7 was treated with acid to remove the Boc 
and TBS protecting groups.  The resulting hydrochloride salt was directly coupled to acid 
6 using HATU to give the protected linear precursor 5.  This sequence is shown in 
Scheme 3.5.  
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Scheme 3.5: Synthesis of linear precursor 5. 
 
The next two steps in the synthesis were the removal of the Troc and allyl groups to free 
the linear precursor for cyclization.  The Troc group was removed to afford free amine 14 
(Scheme 3.6). This reaction proceeded in excellent yield using a Cd/Pb couple, a 
procedure  described by Anderson.8  
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Scheme 3.6:  Removal of Troc group. 
 
The allyl group proved to be a major roadblock in the synthesis.  The conditions tried to 
effect this protecting groups removal (Scheme 3.7) are summarized in Table 2.1.  Initial 
conditions tried (Pd(PPh3)4, morpholine  in THF) gave a complex mixture that could not 
be resolved.  Screening different palladium catalysts, allyl scavengers, reagents and 
solvents did not provide a method to promote the removal of this group. 
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Scheme 3.7:  Attempted removal of the allyl group. 
 
 
 
Table 1: Conditions screened to remove allyl group from 14. 
Condtion Result 
Pd(PPh3)4, morpholine, THF Inseparable mixture 
Pd(PPh3)4, dimedone, THF No reaction 
Pd(PPh3)4, PPTS, THF/H2O No reaction 
Pd2(dba)3, PCy3, dimedone, THF No reaction 
Me3SnOH, 1,2 DCE9 Decomposition 
 
A possible solution to this problem was to remove the allyl group before the Troc group, 
thinking that the free amine might hinder the allyl removal.  This step did not solve the 
problem.  The allyl group was stable to all of the conditions screened, and the synthetic 
strategy toward the Lys3 tamandarin B needed alteration.  Along with the protecting 
group strategy, the site of ring closure was revised. 
With the results of the second generation synthesis of the natural tamandarin B 
macrocycle,10,11 the retrosynthesis of this analog was revised (Scheme 3.8).  Macrocycle 
4 was opened at the Pro4-Me2Tyr5 junction instead of the Hiv-Lys junction as shown in 
Scheme 3.2. 12  
 165 
O
NH
O
O OH
HN O
NHBoc
OO
N
OMe
O
N
O
CbzHN
O
NH
O
O OH
HN
O
N
O
OTMSE
O
OH
O
O
NHBoc
O
TeocN
OMe
OMe
O
O
NTeoc
NHBoc
OH
O
+ +
O
BocN
N OTMSE
O
O
HN
O
OH
CbzHN
CbzHN
4                                                                                          16
17                                         18                                             19  
Scheme 3.8: Revised retrosynthesis of the Lys3 tamandarin B macrocycle. 
 
The revised linear precursor (16) had the terminal acid protected as TMSE (2-
trimethylsilylethyl ester) and the terminal amine was protected with a Teoc group (2-
trimethylsilylethoxy carbamate).  These two protecting groups were chosen because they 
are orthogonal to both Boc and Cbz, so they could withstand the conditions necessary to 
remove either of them.  One of the main challenges of this molecule was the need for a 
third orthogonal nitrogen-protecting group.  These two protecting groups (TMSE and 
Teoc) are labile under treatment with a source of fluoride ion, while Boc is acid labile 
and Cbz is removed by hydrogenolysis conditions.  Also the linear precursor termini were 
not protected as Cbz and benzyl for practical considerations.  The procedures for 
removing these groups are usually very reliable.  The terminal lysine nitrogen was 
protected as a Cbz carbamate because it would be the last group to be removed and a 
protecting group that could be removed without problems would be optimal.  Linear 
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precursor 16 was then divided into three portions:  the Hiv-Lys-Pro alcohol (17), 
norstatine acid (18, synthesized in Chapter 2, pg. 51), and Tyr-Thr acid (19).  This 
strategy closely resembles the synthesis of the tamandarin B macrocycle discussed in 
Chapter 2 (pg. 57). 
The first segment to be synthesized was alcohol 17 (Scheme 9).  Boc-Pro (20) was 
subjected to EDCI mediated esterification with 2-(trimethylsilyl)ethanol to form ester 21 
in high yield.  Removal of the Boc group under acidic conditions yielded a hydrochloride 
salt, which was directly coupled to protected lysine derivative 22 using DEPC to afford 
23 in 62% yield.  Again, removal of the Boc group from 23 using HCl yielded a salt, 
which was coupled to hydroxy acid 24 using BOP to afford alcohol 17 in 60% yield. 
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Scheme 3.9: The synthesis of alcohol 17. 
 
Since acid 18 had been previously synthesized the only remaining fragment to be 
prepared was Tyr-Thr acid 19.  The first step was Teoc protection of L-tyrosine (25) to 
yield the desired carbamate using freshly prepared Teoc-Cl.13 This product was then 
methylated using dimethyl sulfate and sodium hydroxide to form acid 26.  This acid was 
then reacted with N-Boc-Thr-OBn in the presence of EDCI to form the fully elaborated 
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variant of 19 as its benzyl ester.  Hydrogenolysis using palladium on carbon yielded acid 
19 in quantitative yield. 
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O 1) Teoc-Cl, NaHCO3, THF/H2O (68%)
2) Me2SO4, KOH, THF, then H2O (75%)
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2) H2, Pd/C, MeOH (99%)
25 26
19
OMe
NTeoc
O
O
NHBocO
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Scheme 3.10:  Synthesis of acid fragment 19. 
 
With all three desired fragments in hand the linear precursor was assembled.  Acid 19 
was esterified with 17 using EDCI and DMAP to furnish 27.  Fragment 27 was then 
treated with HCl in dioxane to cleave the N,O-acetal and remove the Boc group to afford 
a hydrochloride salt which was directly coupled to acid 19 to form linear precursor 16. 
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Scheme 3.11: Synthesis of linear precursor 16. 
 
 Linear precursor 16 was then treated with TBAF to facilitate removal of the two terminal 
silyl protecting groups.  Unfortunately the isolated product was not the free linear 
precursor.  The product resulted from the hydrolysis of the Tyr-Thr ester and removal of 
the TMSE group (28, Scheme 3.12). 
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Scheme 3.12:  Initial product of treatment of 16 with TBAF. 
 
This unexpected result was caused by the varying amounts of water in the reagent.  The 
commercial source of TBAF usually contains up to 5% water.  This water along with the 
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basic reagent can easily result in the hydrolysis of ester bonds.  Two potential solutions to 
this problem were available: either to buffer the basicity of TBAF with a mild acid or to 
use an anhydrous source of fluoride ion (Scheme 3.13).  The results of this study are 
displayed in Table 3.2. 
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Scheme 3.13: Attempts to remove protecting groups to form 18. 
 
 
 
Table 3.2:  Conditions screened to remove silyl protecting groups. 
entry reagent and solvent temperature (° C) result 
1 TBAF, THF 0 or 25 28 
2 TBAF, AcOH, THF 25 no reaction 
3 TBAF on SiO2 25 30 
4 TASF, DMF 25 or 40 30 
5 TASF, CH3CN 25, 50, or 80 30 
6 TASF, CH2Cl2 25, 40, or 50 30 
7 KF, 18-crown-6, CH3CN 70 decomposition 
8 HF•pyridine 25 no reaction 
9 5% TFA, CH2Cl2 0 or 25 TMSE, Teoc, and Boc 
removal 
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Adding acetic acid to the reaction mixture (Table 3.2, entry 2) completely quenched the 
reaction, and only starting material was recovered.  Using an anhydrous source of 
fluoride ion was also unsuccessful.  TBAF on silica gel was the first reagent screened 
(Table 3.2, entry 3).14 The product of this reaction was 30.  This product was the result of 
only removing the TMSE group.  These conditions did not promote the removal of the 
Teoc group.  Next attention was turned to the reagent TASF (Table 3.2, entries 3-6).15,16 
This reagent, regardless of solvent and temperature gave the same product (30) as TBAF 
on silica gel.  The next conditions tried were potassium fluoride, 18-crown-6, in CH3CN 
(Table, 3.2, entry 7).  These were the original conditions to remove this group described 
in the seminal work of Carpino.17 These conditions only resulted in decomposition of the 
starting material.  The next set of conditions screened were acid promoted removal of the 
protecting groups using HF•pyridine (Table 3.2, entry 8).  These conditions did not 
promote the desired reaction, and resulted in the recovery of starting material.  The final 
reagent tried to remove these protecting groups was dilute TFA in CH2Cl2 (Table 3.2, 
entry 9).  These conditions were successful at removing the two silyl groups, but also 
removed the Boc group.  With these results in mind, the protecting group strategy needed 
to be revised again.  Since the Teoc group could not be removed, it was incompatible in 
this system.  Since the TMSE and Boc groups could both be removed under acidic 
conditions, these two groups could be used to protect the termini of the linear precursor.  
With the Me2Tyr5 residue protected as a Boc carbamate a new protecting group was 
needed to protect the Thr6 amine.  A Troc carbamate was chosen to protect this amine 
because it was removed successfully in linear precursor 5.  This new linear precursor (31) 
is shown in Scheme 3.14. 
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Scheme 3.14:  Revised protecting group strategy of linear precursor. 
An advantage to this approach was that the only changes needed in the linear precursor 
were in the Me2Tyr-Thr fragment, as a result the synthesis of this new linear precursor 
could use the same route up to intermediate 27 as used previously.  The synthesis of this 
new fragment started with dimethylation of N-Boc-Tyr (32) with sodium hydride and 
methyl iodide to form 33.18 Attempts to synthesize N-Troc-threonine benzyl ester in two 
steps from L-threonine by previous methods19 were unsuccessful due to the inability to 
prepare N-Troc-threonine.  To overcome this problem N-Boc-Thr-OBn (34) was treated 
with acid to form a hydrochloride salt, which was reacted under biphasic conditions to 
give the desired compound (35).  An EDCI mediated esterification was used to form an 
ester from alcohol 35 and acid 33. Hydrogenolysis led to the removal of the benzyl group 
to form the desired acid 36 (Scheme 3.15). 
 
 172 
OH
NHBoc
OH
O MeI, NaH, THF
 0 °C to rt, 65%
OMe
NBoc
OH
O
O
OBn
OH
NHBoc
1) 4.0M HCl/dioxane
2)  Troc-Cl, 10% NaHCO3,
     Et2O, 84%
O
OBn
OH
NHTroc
32                                                         33
34                                                                      35
+
1) EDCI, DMAP, THF, 80%
2) H2, Pd/C, MeOH, 64%
OMe
NBoc
O
O
NHTroc
O OH
36
 
Scheme 3.15:  Synthesis of acid 36.  
 
To test the viability of the Troc protecting group in this system, a model study was 
conducted with benzyl ester 37 to test whether it could be removed in a simpler 
compound before advancing to the macrocycle.  The removal of this group proceeded in 
excellent yield using zinc metal in 10% acetic acid/THF to give 38.   
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Scheme 3.16: Model study to remove Troc group. 
 
With confidence that the Troc group could be removed, linear precursor 31 was 
synthesized.  Compound 27 was treated with HCl to fragment the N,O-acetal and remove 
the Boc group to yield a salt, which was then directly coupled to acid 36 to yield the 
desired linear precursor (31) in 61% yield.  The Boc and TMSE protecting groups were 
then removed by treatment with 10% TFA in dichloromethane to afford the TFA salt in 
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quantitative yield.20 This salt was cyclized using BOPCl and triethylamine at 0.0004 M in 
CH2Cl2 to form the Troc protected macrocycle (39) in a modest 27% yield.    
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Scheme 3.17: Synthesis of Troc protected macrocycle 39. 
 
Attention was next turned to removal of the Troc group.  While this transformation was 
possible on the model system, removing this protecting group from 39 to afford 40 
proved to be too difficult (Scheme 3.18).  The conditions tried are summarized in Table 
3.3.   
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Scheme 3.18: Removal of the Troc group. 
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Table 3.3: Conditions tried to affect Troc removal 
condition result 
Zn, 10% AcOH/THF no reaction 
Zn, AcOH no reaction 
Cd, AcOH no reaction 
Cd/Pb, 1M NH4OAc, THF no reaction 
Zn/Pb, 1M NH4OAc, THF no reaction 
SmI2, THF no reaction 
 
All of these conditions resulted in complete recovery of starting material.  A variety of 
reducing agents were screened including Zn,21 Cd,22 Cb/Pb couple,8 Zn/Pb couple,23 and 
SmI2.  The SmI2 conditions to our knowledge have not been used to remove Troc 
carbamates from amines, but Evans used this reagent to remove a Troc carbonate from 
alcohol in his synthesis of cytovaricin.24   
With all of the protecting group problems encountered in the synthesis of this molecule, 
attention was next turned to an approach, which could avoid protecting the amine of the 
Me2Tyr5 residue.  This change was thought to be a viable option due to the fact that the 
reaction to afford macrocycle 39 went in low yield. With that in mind it might be possible 
to couple the primary amine salt of 27 to a Me2Tyr-Thr acid fragment with an 
unprotected secondary amine.   The goal of this strategy was to eliminate the need for a 
third orthogonal nitrogen protecting group, which had been the main setback to all 
attempts to synthesize macrocycle 4.  The new target (41) is shown in Figure 3.2.  This 
molecule has no protecting group on the Me2Tyr nitrogen and the threonine nitrogen is 
protected as a Boc carbamate, which seems vital based on the work previously discussed. 
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Figure 3.2:  New protecting group approach to macrocycle 4. 
 
This new approach would only require modifications to the Tyr-Thr region of the 
molecule.  To make this new fragment N,O-Me2-Cbz-Tyr (42) was esterified with N-Boc-
Thr-OBn (34) to yield a product, that upon exposure to hydrogenolysis conditions led to 
the removal of the Cbz and benzyl groups to give 43 (Scheme 3.19). 
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Scheme 3.19:  Synthesis of acid 43. 
 
This acid (43) was then coupled to the amine salt of 27 to yield linear precursor 41 in 
modest yield with EDCI and HOBt.  Treatment with TASF resulted in the free linear 
precursor, which was then cyclized to afford macrocycle 4 in 35% yield (Scheme 3.20). 
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Scheme 3.20: Synthesis of macrocycle 4. 
 
To complete the synthesis of Lys3 tamandarin M (3) the Boc group was removed to yield 
a hydrochloride salt, which was then coupled to acid 44 (synthesized in Chapter 2, pp...) 
in 47% yield (Scheme 3.21) using BOP. 
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Scheme 3.21:  Completion of the synthesis of  Lys3 tamandarin M (3). 
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3.2) Future Work 
 
The remaining synthetic steps before this molecule is fully elaborated for the desired 
protein affinity studies is the removal of the Cbz group and attaching the desired biotin 
probe molecule.  The biological probe portion (45), which was chosen by Professor 
Crews, will be coupled to the free amine of the lysine residue to yield the desired affinity 
analog (46, Scheme 3.22).25 
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Scheme 3.22: Completion of probe molecule 46. 
 
3.3) Conclusions 
 
Lys3 tamandarin M (3) has been synthesized for use in a protein affinity study.  The Lys3 
tamandarin M macrocycle (4) was made by a method similar to that of the tamandarin B 
macrocycle.  The key to this synthesis was the absence of a protecting group on the 
Me2Tyr nitrogen in the linear precursor.  This molecule could provide information on the 
mechanism of action of these compounds and to possibly reveal an unidentified binding 
protein. 
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3.4) Experimental Section 
General Methods.  All reactions were performed under an argon atmosphere.  
Tetrahydrofuran was distilled over sodium-benzophenone,  dichloromethane was distilled 
over calcium hydride, DMF in Acroseal bottles were used without further purification 
prior to use.  Flash chromatography was carried out on Merck silica gel 60 (240-400 
mesh) using the solvent conditions listed under individual experiments.  Analytical thin-
layer chromatography was performed on Merck silica gel (60F-254) plates (0.25 mm).  
Visualization was effected with ultraviolet light or cerium ammonium molybdate (CAM).  
Proton magnetic resonance spectra (1H NMR) and Carbon magnetic resonance spectra 
(13C NMR) were performed on a Bruker DRX-500 operating at 500 and 125 MHz 
respectively.  IR spectra (IR) were obtained on a Perkin-Elmer 281-B spectrometer.  High 
resolution mass spectra (HRMS) were obtained on a Micromass Autospec or a Waters 
LCTOF-Xe premier.  Optical rotations were measured on a Jasco P-1010 polarimeter. 
 
 
 N-Boc-Proline-(2-trimethylsilylethyl)ester (21). N-Boc-
Proline (1.00 g, 4.60 mmol) was dissolved in anhydrous 
dichloromethane (23 mL) and cooled to 0o C.  To this solution 
was added EDCI ( 0.89 g, 4.60 mmol), DMAP (0.051g, 0.42 mmol) and 2-(trimethylsilyl) 
ethanol ( 0.61 mL, 4.2 mmol) was added dropwise to the reaction mixture via syringe.  
The reaction was allowed to warm to room temperature and stir overnight.  The solvent 
was evaporated and the residue was redissolved in ethyl acetate (50 mL) .  This solution 
was washed with 10% HCl (25 mL), saturated sodium bicarbonate (25 mL), brine (25 
mL), and dried over MgSO4. The solvent was evaporated to yield the product (1.32g, 
N
Boc
OTMSE
O
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90%) as an oil. Rf 0.68 (30% acetone/hexanes); 1H NMR: (500 MHz, CDCl3) δ 0.04 (m, 
9H), 0.99 (m, 2H), 1.44 (m, 9H), 1.89 (m, 3H), 2.20 (m, 1H), 3.46 (m, 2H), 4.25 (m, 3H); 
13C NMR:  (125 MHz, CDCl3) δ -1.6, 17.3, 23.5, 24.2, 28.3, 29.8, 30.8, 46.4, 58.9, 63.1, 
79.6, 153.8, 173.3; IR (cm-1):  2954, 1745, 1703, 1454, 1396, 1250, 1163, 1121; HRMS 
(ES) m/z; calcd for C15H29NO4SiNa (M+Na)+: 338.1764, found: 338.1765; 
! 
"[ ]D
28-44.3 (c 
1.0, CHCl3). 
 
 
Nα−Boc-Nε-Cbz-lysylproline-2-
(trimethylsilylester) (23). 
N-Boc-Proline-(2-trimethylsilylethyl)ester (21) 
(2.55 g, 8.1 mmol) was dissolved in 4.0M HCl in 
dioxane (10 mL).  After 1.5 h the starting material had been consumed.  The solvent was 
evaporated and the material was redissolved in dichloromethane and evaporated again to 
recover the salt (2.03 g, quant).  The salt was dissolved in DMF (15 mL) and cooled to 0o 
C.  To this was added Nα-Boc-Nε−Cbz-Lysine (22) (2.80 g, 7.4 mmol), DEPC (1.80 mL, 
11.80 mmol) and triethylamine (2.56 mL, 18.5 mmol).  The reaction was allowed to 
warm to room temperature and stir overnight.  The reaction was diluted with ethyl acetate 
(30 mL) and washed with 10% HCl (20 mL), water (20 mL), saturated sodium 
bicarbonate (20 mL), and brine (20 mL).  The organic phase was dried over MgSO4, 
filtered, and evaporated to yield the crude product.  Purification by column 
chromatography (30% acetone/hexanes) yielded the product (2.66g, 62%) as a clear oil. 
Rf 0.39 (30% acetone/hexanes); 1H NMR: (500 MHz, CDCl3) δ 0.27 (s, 9H), 0.96 (t, 
J=8.17 Hz, 2H), 1.41 (m, 12H), 1.61 (m, 3H), 1.76 (m, 1H), 1.97 (m, 3H),  2.2 (m, 1H), 
N
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3.21 (m, 2H), 3.59 (m, 1H), 3.71 (m, 1H)  4.18 (t, J=9.3 Hz, 2H) 4.44  (m, 1H), 4.49 (m, 
1H), 5.11 (m, 1H), 5.31 (d, J=6.33 Hz, 1H), 7.34 (m, 5H); 13C NMR: (125 MHz, CDCl3): 
δ -1.6, 17.2, 21.8, 24.8, 28.3, 28.8, 29.1, 32.3, 40.6, 46.9, 51.4, 58.9, 63.5, 66.4, 79.5, 
127.9, 128.4, 136.7, 155.6, 156.4, 171.0, 172.0; IR (cm-1) 3330, 2951, 1714, 1652, 1515, 
1456, 1456, 1249, 1170; HRMS (ES) m/z calcd for C30H49N3O6SiNa (M+Na)+: 600.3081 
found: 600.3088; 
! 
["]D28-31.4 (c 1.04, CHCl3). 
 
Alcohol 17. Nα-Boc-Nε−Cbz-Lysylproline-(2-
trimethylsilylethyl)ester (2.66 g, 4.60 mmol) 
was dissolved in 4.0 M HCl/dioxane (15 mL).  
This solution was allowed to stir at room 
temperature for 2 h.  After this time the reaction 
appeared to be complete by TLC.  The solvent was evaporated under reduced pressure to 
yield the HCl salt as a white foam (2.36 g, quantitative).  The salt was dissolved in 
anhydrous dichloromethane (27 mL) and cooled to 0o C.  To this solution was added N-
methylmorpholine (1.26 mL, 11.50 mmol), BOP (2.26 g, 5.10 mmol) and 2S-
hydroxyisovaleric acid (24) (0.60 g, 5.10 mmol).  The reaction was allowed to warm to 
room temperature and stir overnight.  The reaction was diluted with ethyl acetate (20 mL) 
and washed with 10% HCl (15 mL), saturated sodium bicarbonate (15 mL), brine (15 
mL), and dried over MgSO4.  The crude product was purified by column chromatography 
(2025% acetone/hexanes) to yield the product (1.46 g, 55%) as a clear oil.  Rf 0.18 
(30% acetone/hexanes); 1H NMR (500 MHz, CDCl3) δ 0.03 (s, 9H), 0.85 (d, J= 6.76 Hz, 
3H), 0.98 (m, 5H), 1.36-1.78 (m, 8H), 1.80-2.27 (m, 6H), 2.58 (m, 1H), 3.21 (d, J= 6.08 
N
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Hz, 2H), 3.62 (m, 1H), 3.76 (m, 1H), 4.19 (t, J= 8.71 Hz, 2H), 4.48 (dd, J= 9.58, 4.67 Hz, 
1H), 4.78 (m, 1H), 5.10 (m, 2H), 7.35 (m, 5H); 13C NMR: (125 MHz, CDCl3) δ -1.6, 
15.5, 17.2, 19.1, 22.0, 24.8, 28.8, 29.1, 29.6, 31.6, 40.5, 47.1, 49.8, 59.0, 59.3, 63.5, 64.5, 
66.3, 75.9, 127.8, 127.9, 128.3, 136.7, 156.4, 171.1, 171.8, 173.7; IR (cm-1)  3376, 2956, 
1719, 1654, 1552, 1458, 1250; HRMS (ES) m/z calcd for C29H47N3O7SiNa (M+H)+: 
578.3263 found: 578.3284; 
! 
["]D27 -44.5 (c 1.06, CHCl3). 
 
N-Teoc-L-Tyrosine. L-Tyrosine (6.18 g, 34.11 mmol) and sodium 
bicarbonate ( 10.03 g, 119 mmol) were suspended in deionized 
water (170 mL). Teoc-Cl ( 6.78 g, 37.5 mmol) was dissolved in 
THF (170 mL) and added dropwise to the reaction mixture. The 
reaction was allowed to stir overnight. THF was evaporated and the remaining aqueous 
layer was extracted with diethyl ether (50 mL x 2).  The combined organic phase was 
extracted with 1M NaOH (2 x 20 mL). The combined aqueous layers were cooled to 0° C 
and acidified to pH 4 with 50% HCl.  The acidified aqueous phase was extracted with 
ethyl acetate (3 x 50 mL).  The organic extracts were washed with acidified brine and 
dried over MgSO4.  The solvent was evaporated to yield the product as a white foam 
(2.07g, 66%).  1H NMR (500 MHz, CDCl3) δ 0.03 (s, 9H), 0.97 (m, 2H), 3.08 (m, 3H), 
4.16 (m, 2H), 4.62 (s, 1H), 5.04 (s, 1H), 6.75 (d, J=7.41 Hz, 2H), 7.03 (d, J=7.41, 2H); 
13C NMR (125 MHz, CDCl3) δ -1.6, 17.6, 37.1, 54.6, 63.9, 115,7, 130.5, 154.9, 175.4; 
HRMS (ES) m/z calcd for C15H23NO5SiNa (M+Na)+ : 348.1244, found: 348.1237; [α]
! 
D
30  
+42.7 (c 1.05, CHCl3). 
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N,O-Dimethyl-N-(2-trimethylsilylethoxycarbonyl)tyrosine (28). 
N-Teoc-L-Tyrosine (1g, 3.1 mmol) was dissolved in anhydrous 
THF (31 mL).  To this solution was added dimethyl sulfate (1.9 
mL, 20.2 mmol), potassium hydroxide (1.74g, 31 mmol), and 
tetrabutylammonium bisulfate (0.10g, 10% wt).  After 2 h the reaction flask was cooled 
to 0 oC.  Deionized water (31 mL) was added dropwise.  After 3 h the solvent was 
evaporated and the remaining aqueous mixture was extracted with diethyl ether (2 x 20 
mL). The combined diethyl ether extracts were washed  with saturated sodium 
bicarbonate (2 x 25 mL).  The combined aqueous layers were acidified to pH 4 with solid 
citric acid. The acidified aqueous layer was extracted with ethyl acetate (3 x 50 mL), 
dried over MgSO4,  filtered and the solvent evaporated to yield the crude product as a 
yellow oil.  Purification by flash chromatography (5% MeOH/CHCl3) yielded the pure 
product (0.72g, 70%).   1H NMR (500 MHz, CDCl3) δ 0.01 (s, 9H), 0.92 (m, 2H), 2.80 
(m, 3H), 3.00 (m, 1H), 3.28 (m, 1H), 3.78 (s, 3H), 4.11 (m, 2H), 4.84 (m, 1H), 6.82 (d, 
J=8.46 Hz, 2H), 7.11 (m, 2H); 13C NMR (125 MHz, CDCl3) δ -1.3, 17.9, 32.5, 34.1, 
34.5, 55.6, 60.7, 61.2, 63.9, 64.6, 114.3, 129.2, 130.1, 130.6, 157.6, 158.7, 159.0, 175.8; 
IR (cm-1) 2954, 1701, 1654, 1514, 1249, 1179, 1037; HRMS (ES) m/z calcd for 
C17H27NO5SiNa (M+Na)+: 376.1557, found: 376.1562; [α]
! 
D
28  -1.4 (c 0.54, CHCl3). 
 
N-Boc-L-Threonine benzylester. N-Boc-L-Threonine (5.0 g, 22.8 
mmol) was dissolved in anhydrous DMF (75 mL) and cooled to 0 
°C.  To this solution was added benzyl bromide (5.42 mL, 45.6 
mmol) and sodium carbonate (7.28 g, 68.4 mmol).  The reaction was allowed to warm to 
OMe
NTeoc
OH
O
O
OBn
OH
NHBoc
 183 
room temperature and stir overnight.  The reaction was diluted with ethyl acetate (150 
mL) and was washed with water (2 x 50 mL), 10 % HCl (30 mL), saturated NaHCO3 (30 
mL), and brine (30 mL).  The organic layer was dried over Na2SO4, filtered and the 
solvent was evaporated to yield the crude product.  The crude product was purified by 
flash chromatography (15% acetone/hexanes) to yield the pure product (6.22 g, 88 %) as 
a clear oil. Rf 0.34 (30% acetone/hexanes); 1H NMR (500 MHz, CDCl3) δ 1.23 (d, J= 
2.17 Hz, 3H), 1.44 (s, 9H), 2.04 (s, 1H), 4.31 (s, 1H), 5.20 (q, J= 5.38 Hz, 2H), 5.33 9 (s, 
1H), 7.35 (m, 5H); 13C NMR (125 MHz, CDCl3) δ 19.9, 28.2, 58.7, 67.1, 68.1, 128.1, 
128.4, 128.5, 135.3, 156.0, 171.3; IR (cm-1): 3378, 2974, 2930, 1716, 1514, 1163; HRMS 
(ES) m/z calcd for C16H23NO5Na (M + Na)+: 332.1474, found: 332.1485; 
! 
"[ ]D
26 -18.9 (c  
0.5, MeOH). 
 
 
N,O-Me2-N-Teoc-Tyrosine-O-(N-Boc)-Threonine-
benzyl ester. N,O-Dimethyl-N-Teoc-tyrosine ( 0.50 g, 1.4 
mmol) and N-Boc-threonine benzyl ester (0.40 g, 1.3 
mmol) were dissolved in anhydrous dichloromethane (7 
mL).  To this solution was added DMAP ( 15 mg, 0.13 
mmol) and EDCI (0.30 g, 1.5 mmol).  The reaction was 
allowed to warm slowly to room temperature. After 3 h the reaction mixture was diluted 
with dichloromethane (25 mL).  This solution was then washed with 10% HCl (20 mL), 
saturated sodium bicarbonate (20 mL) and brine (20 mL), dried over MgSO4, and the 
solvent evaporated to yield crude product. Purification by flash chromatography (15% 
acetone/hexanes) yielded  the product (0.44g, 50%) as a clear oil. Rf  0.42 (30% 
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acetone/hexanes); 1H NMR (500 MHz, CDCl3) δ (s, 9H), 2.67 (m, 3H), 2.86 (m, 1H), 
3.13 (m, 1H), 3.76 (s, 3H), 4.08 (m, 2H), 4.46 (m, 1H), 4.73 (m, 1H), 5.14 (m, 3H), 5.46 
(m, 1H), 6.81 (d, J= 8.5 Hz, 2H), 7.06 (m, 2H), 7.35 (m, 5H); 13C NMR: (125 MHz, 
CDCl3)  δ -1.4, 17.0, 17.7, 28.0, 31.6, 33.7, 55.1, 57.3, 60.3, 64.1, 67.6, 71.6, 82.4, 114.1, 
128.4, 128.6, 128.9, 155.9, 156.8, 158.4, 169.8, 170.0;  HRMS (ES) m/z calcd for 
C33H48N2O9Na (M + Na)+: 667.3027, found: 667.3038; [α]
! 
D
28-13.4 (c 1.0, CHCl3).  
 
N,O-Me2-N-Teoc-Tyrosine-O-(N-Boc)-Threonine (19). 
The corresponding benzyl ester  (0.38 g, 0.59 mmol) was 
dissolved in anhydrous methanol (4 mL).  To this solution 
was added 10% Pd/C (38 mg, 10% wt).  The reaction vessel 
was evacuated and purged with hydrogen (3x).  The 
reaction was allowed to stir for 24 h at which time it was diluted with MeOH (25 mL) 
and filtered through a pad of Celite.  Evaporation of the solvent led to the product (0.33 g, 
quantitative) that was used without further purification. 
 
 
Oxazolidine 27.  Oxazolidine acid 81 
(0.178 g, 0.56 mmol) was dissolved in 
tetrahydrofuran (6 mL).  To this solution 
was added alcohol 17 (0.310 g, 0.56 mmol), 
EDCI (0.123 g, 0.64 mmol), and DMAP 
(0.65 g, 0.53 mmol).  The reaction was 
allowed to stir for 18 h.  The reaction mixture was diluted with dichloromethane (20 mL), 
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washed with 10% HCl (10 mL), saturated sodium bicarbonate (10 mL), brine (10 mL), 
dried over Na2SO4, filtered and the solvent evaporated.  Flash chromatography (1020% 
acetone/hexanes) yielded the product (0.338 g, 73%) as a white foam. Rf 0.52 (50% 
acetone/hexanes); 1H NMR (500 MHz, CDCl3) δ 0.04 (s, 9H), 0.85-0.92 (m, 14H), 1.39 
(s, 9H), 1.46 (s, 6H), 1.50 (s, 2H), 1.62 (m, 2H), 1.74-1.99 (m, 5H), 2.08-2.32 (m, 2H), 
2.70 (d, J= 6.05 Hz, 2H), 3.11 (s, 2H), 3.46-3.61 (m, 2H), 3.70 (s, 1H), 3.83 (s, 1H), 4.10 
(dd, J= 8.95, 6.69 Hz, 2H), 4.37 (dd, J= 8.57, 4.87 Hz, 2H), 4.68 (q, J= 7.30 Hz, 1H), 
4.98 (m, 3H), 5.27 (m, 1H), 6.89 (d, J= 7.60 Hz, 1H), 7.23 (m, 5H); 13C NMR (125 MHz, 
CDCl3) δ -1.6, 16.9, 17.1, 18.6, 21.5, 21.8, 22.4, 24.8, 26.0, 26.6, 28.3, 28.8, 28.9, 30.5, 
31.8, 34.7, 40.4, 46.9, 50.0, 58.8, 63.2, 63.5, 66.2, 73.0, 78.3, 79.5, 92.5, 127.8, 128.0, 
128.3, 136.7, 153.2, 156.4, 168.7, 169.6, 169.8, 171.8; IR (cm-1) 3380, 2961, 1737, 1724, 
1690, 1651, 1383, 1248, 1173; HRMS (ES) m/z calcd for C44H72N4O11SiNa (M + Na)+: 
883.4865, found: 883.4847; 
! 
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21-25.7 (c 1.04, CH2Cl2). 
Linear precursor (16).  
Oxazolidine 27 (0.40 g, 0.46 
mmol) was dissolved in 4.0 M 
HCl in dioxane.  After 1.5 h the 
solvent was removed under 
reduced pressure to yield the 
HCl salt as a white foam (0.35 
g, quantitative).  This salt was 
dissolved in DMF (4 mL) and cooled to 0 °C.  To this solution was added acid 19 (0.35 g, 
0.43 mmol), DIPEA (0.32 mL, 1.80 mmol) and HATU (0.18g, 0.46 mmoL).  The 
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reaction was allowed to warm to room temperature and stir overnight. The reaction was 
diluted with EtOAc, washed with 10% HCl, saturated sodium bicarbonate, brine, dried 
over Na2SO4, filtered, and evaporated to yield the product (0.38 g, 70%) as a white solid.  
Rf 0.59 (1:2 hexanes/EtOAc); 1H NMR (500 MHz, CDCl3) δ 0.02 (s, 18H), 0.84 (m, 2H), 
0.94 (m, 14H), 1.14-1.27 (m, 4H), 1.44 (s, 9H), 1.61 (s, 6H), 1.78 (m, 1H), 2.00 (m, 4H), 
2.22 (m, 2H), 2.57 (m, 1H), 2.70 (m, 1H), 2.79 (s, 3H), 2.94 (m, 1H), 3.18 (m, 3H), 3.60 
(m, 1H), 3.76 (s, 3H), 3.94-4.24 (m, 6H), 4.28 (m, 1H), 4.43 (m, 1H), 4.76 (m, 2H), 4.97 
(m, 1H), 5.08 (s, 2H), 5.14 (m, 1H), 5.21 (m, 1H), 5.29 (m, 1H), 5.48 (m, 1H), 6.80 (d, J= 
8.30 Hz, 2H), 7.09 (d, J= 8.15 Hz, 2H), 7.34 (m, 5H), 7.42 (m, 1H); 13C NMR (125 MHz, 
CDCl3) δ -1.20, 13.4, 14.4, 15.8, 17.1, 17.2, 17.6, 19.0, 19.4, 20.5, 22.2, 25.1, 25.2, 28.1, 
28.4, 28.5, 29.2, 29.8, 29.9, 30.6, 31.2, 31.6, 31.8, 32.1, 32.2, 39.4, 40.8, 47.4, 50.3, 50.5, 
54.4, 59.2, 59.3, 64.0, 66.7, 69.3, 76.4, 78.2, 81.1, 114.2, 128.2, 1305, 137.0, 156.9, 
166.3, 169.8, 170.9, 171.1, 172.0, 172.2, 173.6;  IR (cm-1)  3334, 2958, 1737, 1721, 1639, 
1514, 1249, 1175; HRMS (ES) m/z calcd for C62H100N6O17Si2Na (M + Na)+: 1279.6582, 
found: 1279.6608; 
! 
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23.8  -28.14 (c 0.3, CHCl3). 
N-Troc-Thr-OBn (35). Boc-Thr-OBn (3.67 g, 12.2 mmol) was 
dissolved in 4.0 M HCl in dioxane (15 mL).  This solution was 
allowed to stir at room temperature for 4 h.  The solvent was 
evaporated to yield the HCl salt in quantitative yield.  The salt was added in portions to a 
biphasic mixture of 10% NaHCO3 (7 mL), diethyl ether (7 mL) and NaHCO3 ( 1.02 g, 
12.2 mmol) cooled to 0 °C. Troc-Cl (1.64 mL, 12.2 mmol) in diethyl ether (5 mL) was 
added to the reaction mixture over 1.5 h.  The reaction was allowed to warm to room 
temperature and stir overnight. 10 % NaHCO3 (15 mL) was added to this solution and the 
O
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mixture stirred for an additional 2 h.  Diethyl ether (40 mL) was then added.  The layers 
were separated and the aqueous phase was extracted with diethyl ether (3 x 50 mL).   The 
combined organic extracts were washed with water (25 mL), brine (25 mL) and dried 
over Na2SO4.  The solvent was evaporated under reduced pressure to yield the product 
(3.92 g, 84 %) as a yellow oil.  Rf  0.42 (30% EtOAc/Hexanes); 1H NMR (500 MHz, 
CDCl3) δ 1.25 (d, J= 6.25 Hz, 3H), 2.30 (m, 1H), 4.37 (m, 2H) 4.69 (d, J= 11.99 Hz, 1H), 
4.79 (d, J=12.04 Hz, 1H), 5.19 (m, 2H), 5.97 (d, J= 8.95 Hz, 1H), 7.35 (m, 5H); 13C 
NMR (125 MHz, CDCl3) δ 19.8, 25.5, 59.4, 67.5, 67.8, 74.7, 95.3, 128.2, 128.5, 128.6, 
130.0, 155.0, 170.5; IR (cm-1): 3310, 2977, 1716, 1508, 1456, 1395, 1262, 1204; HRMS 
(ES) m/z calcd for C14H16Cl3NO5Na (M + Na)+: 405.9992 found: 405.9992; 
! 
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24    -17.6  
(c 1.04, MeOH). 
 
N,O-Me2-Boc-Tyr-O-(N-Troc)-Thr-OBn. N,O-Me2-Boc 
Tyr (1.85 g, 6 mmol) was dissolved in anhydrous THF ( 24 
mL) and cooled to 0 °C.  To this solution was added Troc-
Thr-OBn (1.54 g, 4 mmol), EDCI (1.23 g, 6.4 mmol) and 
DMAP (0.73g, .6 mmol).  The reaction mixture was allowed 
to warm to room temperature and stir overnight.  It was 
diluted with EtOAc (50 mL) and washed with 10% KHSO4 (25 mL), saturated NaHCO3 
(25 mL) and brine (25 mL).  The organic layer was dried over Na2SO4 and the solvent 
was evaporated to yield the crude product.  The crude product was purified by column 
chromatography (1015% EtOAc/Hexanes) to yield the product (2.16g, 80%) as a clear 
oil.  Rf  0.55 (30% EtOAc, Hexanes); 1H NMR (500 MHz, CDCl3) δ 1.07−1.28 (m, 12H), 
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2.61 (s, 3H), 2.87 (m, 1H), 3.11 (m, 1H), 3.77 (s, 3H), 4.51 (m, 1H), 4.74 (m, 3H), 5.13 
(m, 2H), 5.21 (m, 1H), 5.79 (s, 1H), 6.82 (m, 2H), 7.06 (m, 2H), 7.34 (m, 5H); 13C NMR 
(125 MHz, CDCl3) δ 16.7, 22.6, 25.2, 28.2, 31.3, 33.9, 34.6, 55.2, 57.7, 60.3, 67.8, 71.0, 
74.7, 80.2, 95.2, 113.9, 127.6, 128.5, 128.6, 129.7, 130.2, 134.9, 154.9, 158.7, 168.9, 
170.2; IR (cm-1): 3421, 3319, 2975, 2934, 1732, 1716, 1702, 1514, 1249, 1162; HRMS 
(ES) m/z calcd for C30H37Cl3N2O7Na (M + Na)+: 697.1464, found: 697.1462; 
! 
"[ ]D
25 -14.8  
(c = 0.65, MeOH). 
 
 
 N,O-Me2-Boc-Tyr-Troc-Thr-OH (36).  N,O-Me2-Boc-Tyr-
Troc-Thr-OBn (3.27 g, 4.84 mmol) was dissolved in THF (130 
mL).  To this solution was added 10% Pd/C (0.32 g, 10% wt).  
The reaction vessel was evacuated and purged with hydrogen.  
The reaction was allowed to stir overnight then filtered through 
a pad of Celite and the residue rinsed thoroughly with THF.  
The solvent was evaporated to yield the product as a white solid (1.78 g, 63%) which was 
used without further purification. 
 
Protected linear precursor. 
oxazolidine 27 (69 mg, 0.080 
mmol) was dissolved in 4.0 M 
HCl in dioxane (2 mL) and was 
allowed to stir to 2 h at which 
time the solvent was removed 
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and dried under reduced pressure to yield the HCl salt (61 mg, quantitative) as a white 
solid.  This HCl salt (61 mg, 0.080 mmol was dissolved in anhydrous DMF (1 mL) and 
cooled to 0 °C. Acid 36 (56 mg, 0.096 mmol), DIPEA (56 µL, 0.12 mmol), and HATU 
(46 mg, 0.096 mmol) were added and the reaction was allowed to warm to room 
temperature and stir overnight.  The reaction was diluted with ethyl acetate (25 mL), 
washed with 10% HCl (15 mL), saturated NaHCO3 (15 mL), and brine (15 mL).  The 
organic layer was dried over Na2SO4, filtered and evaporated to yield the crude product 
as a brown oil.  Purification by column chromatography (202535% acetone/hexanes) 
yielded the product (63 mg, 61%) as an off white foam.  Rf 0.57 (60% acetone/hexanes) 
1H NMR (500 MHz, CDCl3) δ 0.00 (s, 9H), 0.93 (m, 14H), 1.03 (m, 2H), 1.39 (m, 12H), 
1.60 (m, 6H), 1.71 (m, 1H), 1.96 (m, 4H), 2.21 (m, 2H), 2.52 (m, 1H), 2.63 (m, 1H), 2.81 
(m, 3H), 2.85-2.99 (m, 2H), 3.16 (m, 2H), 3.59 (m, 2H), 3.71 (m, 1H), 3.74 (s, 3H), 3.82-
4.00 (m, 2H), 4.06-4.25 (m, 3H), 4.29 (s, 1H), 4.41 (m, 2H), 4.63 (m, 3H), 4.95-5.16 (m, 
3H), 5.23 (m, 1H), 6.79 (m, 2H), 7.06 (m, 2H), 7.31 (m, 5H); 13C NMR (125 MHz, 
CDCl3) δ -1.5, 11.5, 15.9, 17.2, 18.8, 20.5, 20.8, 22.2, 24.8, 25.3, 27.9, 28.4, 29.0, 29.1, 
30.4, 30.7, 31.6, 34.2, 34.7, 36.5, 36.9, 38.9, 40.6, 46.2, 47.2, 50.1, 55.3, 59.1, 63.7, 66.5, 
68.9, 74.8, 78.2, 80.6, 95.4, 114.1, 128.0, 128.1, 128.5, 129.9, 136.9, 154.6, 156.6, 158.5, 
169.3, 169.6, 170.6, 170.9, 171.2, 171.5, 171.7; IR (cm-1) 3326, 2953, 1736, 1714, 1699, 
1636, 1514, 1455, 1248; HRMS (ES) m/z calcd for C59H89Cl3N6O17SiNa (M + Na)+: 
1309.5016, found: 1309.4969; 
! 
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25 -20.7 (c 0.5, CH2Cl2). 
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Macrocycle 39. Linear precursor (164 
mg, 0.151 mmol) was dissolved in 
anhydrous dichloromethane (8 mL) and to 
this solution was added trifluoroacetic 
acid (2 mL).  The reaction was allowed to 
stir for 7 h at which time 1H NMR 
revealed removal of both the desired 
protecting groups.  The solvent was evaporated to yield the TFA salt as a brown oil. This 
salt was dissolved in anhydrous dichloromethane (410 mL) and cooled to -10 °C.  To this 
was added BOP-Cl (39 mg, 0.153 mmol) and triethylamine (53 µL, 0.460 mmol).  The 
reaction was allowed to warm to room temperature and stir overnight.  The following 
day, additional portions of BOP-Cl (39 mg, 0.153 mmol) and triethylamine (53 µL, 0.460 
mmol) were added and the reaction was allowed to stir for an additional 5 days.  The 
solvent was evaporated and the remaining residue was dissolved in dichloromethane (50 
mL) and washed with 10% KHSO4 (20 mL), 5% NaHCO3 (20 mL), brine (20 mL).  The 
organic layer was dried over Na2SO4, filtered and concentrated to yield the crude product, 
which was purified by column chromatography (1540% EtOAc/CH2Cl2) to yield the 
product (36 mg, 27%) as a white solid. Rf 0.27 (50% EtOAc/CH2Cl2); 1H NMR (500 
MHz, CDCl3) δ 0.80-1.01 (m, 12H), 1.15-1.28 (m, 2H), 1.33-1.48 (m, 4H), 1.70-1.81 (m, 
2H), 1.92-2.03 (m, 2H), 2.04-2.13 (m, 2H), 21.5-2.26 (m, 2H), 2.40 (dd, J= 16.73, 8.80 
Hz, 1H), 2.56 (s, 3H), 2.79-2.86 (m, 1H), 3.01 (d, J= 3.11 Hz, 1H), 3.10-3.21 (m, 3H), 
3.32 (dd, J= 14.18, 3.93 Hz, 1H), 3.55-3.67 (m, 3H), 3.77 (s, 3H), 3.89 (m, 1H) 4.39 (dd, 
J=  9.28, 2.88 Hz, 1H), 4.54 (m, 1H), 4.61-4.73 (m, 2H), 4.78 (t, J= 9.53 Hz, 1H), 5.00-
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5.08 (m, 3H), 5.11 (dd, J= 6.43, 3.03 Hz, 1H), 5.19 (s, 1H), 5.54 (d, J= 9.25 Hz, 1H), 
6.81 (d, J= 8.25 Hz, 2H), 7.04 (d, J=8.20 Hz, 2H), 7.31 (m, 5H), 7.63 (d, J= 9.30 Hz, 
1H);  13C NMR (125 MHz, CDCl3) δ 14.2, 15.2, 16.8, 17.2, 18.8, 20.2, 24.8, 27.0, 28.0, 
29.7, 30.1, 31.3, 33.9, 38.8, 39.7, 47.2, 48.6, 55.3, 56.8, 57.5, 57.7, 60.4, 65.9, 69.1, 70.7, 
74.6, 78.7, 95.3, 114.1, 128.0, 128.1, 128.4, 129.7, 130.3, 136.8, 154.5, 156.6, 158.7, 
168.4, 169.3, 169.8, 170.5, 173.4; IR (neat): 3341, 2930, 1726, 1655, 1631, 1535, 1458, 
1246;  HRMS (ES) m/z calcd for C49H67Cl3N6O14 (M + Na)+: 1091.3679: found: 
1091.3694; 
! 
"[ ]D
21 -56.1 (c 0.72, CH2Cl2). 
 
N,O-Me2-Cbz-Tyr-Boc-Thr-OBn.  Tyrosine derivative 
42  (1.00 g, 3.23 mmol) was dissolved in THF (20 mL) 
and cooled to 0 °C.  To this solution was added alcohol 
34 (1.33 g, 3.89 mmol), EDCI (0.75 g, 3.89 mmol), and 
DMAP (0.039 g, 0.32 mmol).  The reaction was allowed 
to warm to room temperature and stir overnight.  The reaction was diluted with EtOAc 
(50 mL), washed with 10% HCl (15 mL), saturated sodium bicarbonate (15 mL), brine 
(15 mL), dried over Na2SO4, filtered and concentrated to yield the crude product.  
Purification by flash chromatography (1025% EtOAc/hexanes) yielded the pure 
product  (1.45 g, 71%) as a clear oil.  Rf 0.50 (30% EtOAc/hexanes);  1H  NMR (500 
MHz, CDCl3) δ 1.30 (d, J= 6.40 Hz, 3H), 1.47 (s, 9H), 2.66-2.72 (m, 3H), 2.78-2.98 (m, 
1H), 3.06-3.22 (m, 1H), 3.77 (s, 3H), 4.50 (t, J= 9.25 Hz, 1H), 4.73 (dd, J= 10.23, 5.73 
Hz, 1H), 5.05 (d, J= 3.55 Hz, 1H), 5.07-5.23 (m, 3H), 5.33 (d, J= 9.60 Hz, 1H), 5.47 (dd, 
J= 13.35, 6.45 Hz, 1H), 6.79 (m, 2H), 6.96-7.10 (m, 2H), 7.20-7.41 (m, 10H); 13C NMR 
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(125 MHz, CDCl3) δ 14.1, 16.5, 16.8, 28.1, 31.9, 33.7, 54.9, 56.9, 60.1, 60.6, 67.1, 67.4, 
71.5, 80.0, 113.9, 127.5, 127.8, 128.3, 128.5, 128.6, 129.6, 130.1, 136.5, 155.7, 156.4, 
158.2, 169.6, 169.7; IR (cm-1);   HRMS (ES) m/z calcd for C35H42N2O9Na (M + Na)+: 
657.2788, found: 657.2766; 
! 
"[ ]D
17  -22.3 (c 1.40, CHCl3). 
 
N,O-Me2Tyr-Boc-Thr-OH (43).  N,O-Me2-Cbz-Tyr-Boc-
Thr-OBn (213 mg, 0.34 mmol) was dissolved in MeOH 
(10 mL).  To this was added 10% Pd/C (21 mg, 10% wt.) 
and the reaction flask was evacuated and purged with 
hydrogen.  The reaction was allowed to stir for 12 h at 
which time the mixture was filtered through a pad of celite and rinsed thoroughly with 
MeOH.  The solvent was evaporated to yield the product (137 mg, quantitative) as a 
white solid which was used without further purification. 
 
Linear precursor.  The HCl 
salt of 27 (83 mg, 0.110 
mmol) was dissolved in 
CH2Cl2 (2 mL) and cooled to 
0 °C.  To this solution was 
added acid 43 (45 mg, 0.110 
mmol), EDCI (22 mg, 0.115 mmol), HOBt (16 mg, 0.0115 mmol) and NMM (25 µL, 
0.230 mmol).  The reaction was allowed to warm to room temperature and stir for 48 h.  
The reaction was diluted with EtOAc (30 mL), washed with H2O (10 mL), brine (10 mL), 
dried over Na2SO4, filtered and concentrated.  Purification by flash chromatography 
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(1540 acetone/hexanes) yielded the product (44 mg, 38%) as a white solid.  Rf 0.23 
(50% acetone/hexanes); 1H NMR (CDCl3, 500 MHz) δ 0.02 (s, 9H), 0.8-0.99 (m, 16H), 
1.07 (d, J= 5.45 Hz, 3H), 1.25 (m, 2H), 1.43 (s, 9H), 1.51-1.89 (m, 7H), 1.90-2.06 (m, 
4H), 2.16 (m, 2H), 2.22 (m, 1H), 2.32 (s, 3H), 2.50 (m, 1H), 2.66 (m, 1H), 2.75-2.94 (m, 
2H), 3.17 (m, 2H), 3.36 (m, 1H), 3.60 (m, 1H), 3.76 (s, 3H), 3.77 (s, 1H), 4.04-4.30 (m, 
3H), 4.40 (m, 1H), 4.78 (m, 1H), 4.95 (m, 1H), 5.08 (m, 3H), 5.23-5.50 (m, 2H), 6.82 (m, 
2H), 7.09 (m, 2H) 7.33 (m, 5H); 13C NMR (CDCl3, 125 MHz) δ -1.61, 11.4, 14.0, 15.3, 
16.6, 17.3, 18.7, 20.2, 22.1, 22.5, 24.7, 25.2, 28.1, 28.2, 29.2, 29.9, 30.3, 31.5, 33.5, 34.4, 
34.6, 38.4, 40.5, 47.2, 49.5, 49.9, 55.1, 57.8, 58.7, 59.1, 63.5, 64.5, 66.4, 78.5, 80.3, 
113.8, 114.2, 127.9, 128.4, 130.1, 130.4, 136.7, 156.3, 158.4, 165.6, 169.4, 171.1, 171.3, 
171.1; IR (cm-1) 3442, 3340, 3028, 2977, 1742, 1713, 1514, 1248, 1165; HRMS (ES) m/z 
calcd for C56H89N6O15Si (M + H)+: 1113.6155, found: 1113.6145;   
! 
"[ ]D
20 -45.5 (c 1.71, CH2Cl2) 
 
 
Macrocycle 4.  The previous linear 
precursor (40 mg, 0.36 mmol) was 
dissolved in THF (0.8 mL) and MeCN (0.2 
mL) and cooled to 0 ºC.  To this solution 
was added TASF (32 mg, 0.116 mmol).  
The reaction was allowed to warm to room 
temperature and stir overnight.  The 
reaction mixture was diluted with EtOAc (25 mL) and washed with 10% HCl (2 x 10 
mL), brine (10 mL), dried over Na2SO4, filtered, and concentrated to yield the crude 
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product (29 mg, 81%) as a white foam, which was used without any further purification.  
The crude product was dissolved in CH2Cl2 (20 mL) and loaded in to a syringe.  In a 
separated flask BOP-Cl (29 mg, 0.114 mmol) and NMM (31 µL, 0.285 mmol) were 
added sequentially to CH2Cl2 (20 mL) and this mixture was cooled to -20 ºC.  The crude 
product solution was added to this flask over 5 h using a syringe pump while the reaction 
mixture was kept at -20 ºC.  After the addition was complete the reaction was allowed to 
warm to room temperature and stir for 48 h.  The reaction mixture was washed with 10% 
HCl (20 mL), 5% NaHCO3 (20 mL), brine (20 mL), dried over Na2SO4, filtered, and 
concentrated to yield the crude product.  Purification by flash chromatography (2050% 
EtOAc/CH2Cl2) yielded the product (10 mg, 35%) as an oil.  Rf 0.40 (60% 
EtOAc/CH2Cl2); 1H NMR (CDCl3, 500 MHz) δ 0.74-1.01 (m, 12H), 1.24 (m, 7H), 1.40 
(s, 9H), 1.50-1.69 (m, 6H), 1.73 (m, 2H), 2.01 (m, 2H), 2.08 (m, 2H), 2.18 (m, 1H), 2.45 
(dd, J= 16.8, 6.9Hz, 1H), 2.52-2.74(m, 3H), 2.78-2.94 (m, 1H), 3.04-3.20 (m, 3H), 3.31 
(dd, J= 14.1 Hz, 3.79 Hz, 1H), 3.55 (m, 1H), 3.60-3.69 (m, 1H), 3.71-3.78 (m, 3H), 3.80-
3.86 (m, 1H), 3.92 (s, 1H), 4.28 (m, 1H), 4.55 (t, J= 4.20 Hz, 1H), 4.79 (m, 1H), 4.95-
5.15 (m, 3H), 6.81 (m, 2H), 7.01 (m, 2H), 7.33 (m, 5H), 7.52 (d, J= 9.65 Hz, 1H), 7.85 
(d, J= 8.70 Hz, 1H);  13C NMR (CDCl3, 125 MHz) δ 8.53, 14.1, 15.1, 17.7, 18.5, 20.1, 
22.7, 24.8, 27.3, 27.9, 29.6, 30.1, 30.5, 33.8, 38.1, 38.6, 38.9, 40.7, 45.7, 46.9, 49.5, 52.8, 
55.1, 55.9, 57.2, 59.4, 60.3, 64.3, 65.7, 66.4, 68.8, 71.2, 78.8, 80.1, 113.9, 114.2, 127.9, 
128.0, 129.7, 130.2, 136.7, 155.5, 156.3, 158.5, 168.6, 169.7, 170.0, 170.5, 171.2, 173.0; 
IR (cm-1) 3437, 3339, 2961, 2925, 1731, 1700, 1713, 1667, 1651, 1635, 1537, 1512, 
1452, 1246, 1168, 1021; ; HRMS (ES) m/z calcd for C51H75N6O14 (M + H)+: 995.5341, 
found: 995.5370; 
! 
"[ ]D
19 -50.2 (c 1.20, CH2Cl2). 
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Lys3 Tamandarin M (3).  Macrocycle  4 (12 mg, 0.0121 mmol) was dissolved in EtOAc 
(3 mL) and the solution was cooled to -20 ºC.  HCl gas was bubbled into the solution for 
5 min.  The reaction mixture was allowed to stir at -20 ºC for 1 h and then stirred at 0 ºC 
for an additional 30 min.  At this time the ice bath was removed and argon was bubbled 
through the solution for 30 minutes.  The solvent was evaporated to yield the macrocyclic 
salt (11 mg, 99%) as an off-white solid, which was used without further purification.  The 
salt was dissolved in CH2Cl2 (1 mL) and to this solution was added acid 44 (10 mg, 
0.0181 mmol), BOP (8 mg, 0.0181 mmol) and NMM (5µL, 0.0484 mmol).  The reaction 
was stirred for 24 h.  The reaction was diluted with EtOAc (15 mL), washed with 10% 
HCl (5 mL), 5% NaHCO3 (5 mL), brine (5 mL), dried over Na2SO4, filtered and 
concentrated to yield the crude product.  Purification by flash chromatography (110% 
MeOH/CH2Cl2) yielded the product (8 mg, 47%) as a white solid.  Rf  0.24 (10% 
MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 0.70-1.06 (m, 14H), 1.12-1.44 (m, 16H), 
1.48-1.63 (m, 3H), 1.65-1.92 (m, 11H), 1.95-2.34 (m, 10H), 2.38-2.67 (m, 5H), 3.00 (s, 
3H), 3.07 (m, 3H), 3.15 (m, 1H), 3.31 (m, 1H), 3.42-3.68 (m, 4H), 3.77 (s, 1H), 3.86 (t, 
 196 
J= 9.19 Hz, 1H), 4.13 (m, 2H), 4.52 (m, 3H), 4.70 (t, J= 6.89 Hz, 1H), 4.78 (t, J= 8.68 
Hz, 1H), 4.95-5.12 (m, 3H), 5.21 (m, 1H), 5.35 (m, 1H), 5.53 (s, 1H), 6.23 (s, 1H), 6.82 
(d, J= 8.14 Hz, 2H), 6.90 (d, J= 7.79 Hz, 1H), 7.04 (d, J= 8.19 Hz, 2H), 7.32 (m, 5H), 
7.62 (d, J= 9.24 Hz, 1H), 7.73 (d, J= 9.84 Hz, 1H), 7.81 (m, 1H), 8.36 (d, J= 6.40 Hz, 
1H); 13C NMR (CDCl3, 125 MHz) δ 14.2, 15.7, 15.9, 16.6, 17.8, 18.8, 20.1, 21.7, 22.7, 
23.2, 25.6, 25.0, 25.2, 25.5, 25.8, 27.3, 28.0, 28.4, 28.9, 29.4, 29.7, 30.1, 30.4, 30.9, 31.2, 
31.8, 32.0, 32.8, 33.8, 36.1, 38.7, 39.3, 40.8, 47.1, 49.5, 52.1, 54.1, 55.3, 55.9, 56.8, 57.1, 
57.3, 58.2, 65.3, 66.6, 68.7, 69.5, 70.8, 79.3, 114.1, 128.1, 128.2, 128.5, 129.7, 130.0, 
130.5, 136.7, 156.5, 158.6, 168.8, 169.5, 169.9, 170.3, 170.4, 170.9, 171.3, 173.3, 173.4, 
173.6, 176.9; IR (cm-1) 3437, 3344, 2956, 2930, 1659, 1651, 1633, 1535, 1455, 1246, 
1091; HRMS (ES) m/z calcd for C71H103N11O20: 1452.7279, found: 1452.7245; 
! 
"[ ]D
22 -24.9  
(c 0.7, CH2Cl2). 
3.5) References 
1 Beidler, D. R., Ahuja, D., Wicha, M. S. & Toogood, P. L. "Inhibition of Protein 
Synthesis by Didemnin B is not Sufficient to Induce Apoptosis in Human 
Mammary Carcinoma (MCF7) Cells." Biochem. Pharmacol. 1999, 58, 1067-
1074. 
2 Crews, C. M., Collins, J. L., Lane, W. S., Snapper, M. L. & Schreiber, S. L. 
"GTP-dependent Binding of the Antiproliferative Agent Didemnin to Elongation 
Factor 1α." J. Biol. Chem. 1994, 269, 15411-15414. 
3 Crews, C. M., Lane, W. S. & Schreiber, S. L. "Didemnin binds to the protein 
palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis." 
Proc. Natl. Acad. Sci. USA 1996, 93, 4316-4319. 
4 Vera, M. D., Pfizenmayer, A. J., Ding, X., Xiao, D. & Joullié, M. M. 
"[Lys3]Didemnins as Potential Affinity Ligands." Bioorg. Med. Chem. Lett. 2001, 
11, 13-16. 
5 Vera, M. D. "Synthetic and Medicinal Chemistry of the Didemnins", University 
of Pennsylvania, Philadelphia, PA, 2000. 
6 Long, C. M. "Investigations of Novel Ascidian Metabolites" Ph. D. thesis, 
University of Pennsylvania, Philadelphia, 2006. 
 197 
7 Li, W.-R., Ewing, W. R., Harris, B. D. & Joullié, M. M. "Total Synthesis and 
Structural Investigations of Didemnins A, B, and C." J. Am. Chem. Soc. 1990, 
112, 7659-7672. 
8 Dong, Q., Anderson, C. E. & Ciufolini, M. A. "Reductive Cleavage of Troc 
Groups under Neutral Conditions with Cadmium-Lead Couple." Tetrahedron 
Lett. 1995, 36, 5681-5682. 
9 Nicolaou, K. C., Estrada, A. A., Zak, M., Lee, S. H. & Safina, B. S. "A mild and 
selective method for the hydrolysis of esters with trimethyltin hydroxide." Angew. 
Chem., Int. Ed. Engl. 2005, 44, 1378-1382. 
10 Lassen, K. M., Lee, J. & Joullié, M. M. "Synthetic Studies of Tamandarin B Side 
Chain Analogues." J. Org. Chem. 2010, 75, 3027-3036. 
11 Lassen, K. M., Lee, J. & Joullié, M. M. "An efficient synthesis of the tamandarin 
B macrocycle." Tetrahedron Lett. 2010, 51, 1635-1638. 
12 Lassen, K. M. & Joullié, M. M. "Total Synthesis of Lys(3) Tamandarin M: A 
Potential Affinity Ligand." Org. Lett. 2010, 12, 5306-5309. 
13 Sekine, M., Tobe, M., Nagayama, T. & Wada, T. "Synthesis of N-
(trimethylsilylethoxycarbonyl)-deoxycytidine and deoxy-adenosine derivatives as 
key intermediates for the DNA synthesis using fluoride ion-promoted 
deprotection strategy." Lett Org Chem 2004, 1, 179-182. 
14 Sefler, A. M., Kozlowski, M. C., Guo, T. & Bartlett, P. A. "Design, synthesis, and 
evaluation of a depsipeptide mimic of tendamistat." J. Org. Chem. 1997, 62, 93-
102. 
15 Roush, W. R., Coffey, D. S. & Madar, D. J. "Total synthesis of (+)-damavaricin 
D." J. Am. Chem. Soc. 1997, 119, 11331-11332. 
16 Scheidt, K. A. et al. "Tris(dimethylamino)sulfonium difluorotrimethylsilicate, a 
mild reagent for the removal of silicon protecting groups." J. Org. Chem. 1998, 
63, 6436-6437. 
17 Carpino, L. A., Tsao, J. H., Ringsdorf, H., Fell, E. & Hettrich, G. "The [small 
beta]-(trimethylsilyl)ethoxycarbonyl amino-protecting group." J. Chem. Soc., 
Chem. Commun. 1978, 358-359. 
18 Boger, D. L. & Yohannes, D. "Studies on the Total Synthesis of Bouvardin and 
Deoxybouvardin:  Cyclic Hexapeptide Cyclization Studies and Preparation of 
Key Partial Structures." J. Org. Chem. 1988, 53, 487-499. 
19 Yokokawa, F., Inaizumi, A. & Shioiri, T. "Synthetic studies of the cyclic 
depsipeptides bearing the 3-amino-6-hydroxy-2-piperidone (Ahp) unit. Total 
synthesis of the proposed structure of micropeptin T-20." Tetrahedron 2005, 61, 
1459-1480. 
20 Bowers, A. et al. "Total synthesis and biological mode of action of largazole: A 
potent Class I histone deacetylase inhibitor." J. Am. Chem. Soc. 2008, 130, 11219-
11222. 
21 Just, G. & Grozinger, K. "Selective, Mild Cleavage of Trichloroethyl Esters, 
Carbamates, and Carbonates to Carboxylic-Acids, Amines, and Phenols Using 
Zinc-Tetrahydrofuran Ph 4.2-7.2 Buffer." Synthesis-Stuttgart 1976, 457-458. 
 198 
22 Hancock, G., Galpin, I. J. & Morgan, B. A. "Side Reactions and Cadmium 
Catalyzed Removal of the Trichloroethoxycarbonyl (Troc) Protecting Group." 
Tetrahedron Lett. 1982, 23, 249-252. 
23 Overman, L. E. & Freerks, R. L. "Short Total Synthesis of (+/-)-
Perhydrogephyrotoxin." J. Org. Chem. 1981, 46, 2833-2835. 
24 Evans, D. A., Kaldor, S. W., Jones, T. K., Clardy, J. & Stout, T. J. "Total 
Synthesis of the Macrolide Antibiotic Cytovaricin." J. Am. Chem. Soc. 1990, 112, 
7001-7031. 
25 Tae, H. S., Hines, J., Schneekloth, A. R. & Crews, C. M. "Total Synthesis and 
Biological Evaluation of Tyroscherin." Org. Lett. 2010, 12, 4308-4311. 
 
 
 199 
 
 
 
 
 
 
 
3.6) Appendix B: Nuclear Magnetic Resonance and Infrared Spectra Relevant to 
Chapter 3  
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